UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

WASHINGTON, D.C. 2054

	FORM 10-Q	
(Mark One)		
☑ QUARTERLY REPORT PURSUANT TO SECTION 13	OR 15(d) OF THE SECURITIES E	XCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022		
for the quarterly period ended september 50, 2022	OR	
☐ TRANSITION REPORT PURSUANT TO SECT	V	TIES EYCHANCE ACT OF 1034
For the transition period from to		THES EXCHANGE ACT OF 1934
101 the transition period from		
	Commission File Number: 1-644	
COLGATE	C-PALMOLIVE	COMPANY
	name of registrant as specified in its	
Delaware	name of registrant as specified in its	13-1815595
(State or other jurisdiction of incorporation or or	zanization)	(I.R.S. Employer Identification No.)
(State of other jurisdiction of meorporation of org	Samzation)	(i.i.s. Employer ruentimeation 100)
300 Park Avenue		
New York, New York		10022
(Address of principal executive offices)		(Zip Code)
	(212) 310-2000	
(Registr	cant's telephone number, including a	rea code)
Securities registered pursuant to Section 12(b) of the Act:		
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$1.00 par value	CL	New York Stock Exchange
0.500% Notes due 2026	CL26	New York Stock Exchange
0.300% Notes due 2029	CL29	New York Stock Exchange
1.375% Notes due 2034	CL34	New York Stock Exchange
0.875% Notes due 2039	CL39	New York Stock Exchange
	NO CHANGES	
(Former name, former	address and former fiscal year, if ch	anged since last report)
Indicate by check mark whether the registrant (1) has filed all repreceding 12 months (or for such shorter period that the registrant was days. Yes \boxtimes No \square	eports required to be filed by Section 1	3 or 15(d) of the Securities Exchange Act of 1934 during the

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes 🗵 No 🗆

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes \square No \boxtimes Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

 Class
 Shares Outstanding
 Date

 Common stock, \$1.00 par value
 835,214,210
 September 30, 2022

PART I. FINANCIAL INFORMATION

COLGATE-PALMOLIVE COMPANY

Condensed Consolidated Statements of Income

(Dollars in Millions Except Per Share Amounts) (Unaudited)

		Three Mon Septen				Nine Mon Septem		
	' <u>-</u>	2022		2021		2022		2021
Net sales	\$	4,455	\$	4,414	\$	13,338	\$	13,018
Cost of sales		1,907		1,791		5,664		5,202
Gross profit	<u></u>	2,548		2,623		7,674		7,816
Selling, general and administrative expenses		1,634		1,636		4,932		4,809
Other (income) expense, net		(33)		20		51		40
Operating profit		947		967		2,691		2,967
Non-service related postretirement costs		15		16		65		52
Interest (income) expense, net		40		98		98		152
Income before income taxes		892		853		2,528		2,763
Provision for income taxes		210		172		604		613
Net income including noncontrolling interests		682		681		1,924		2,150
Less: Net income attributable to noncontrolling interests		64		47		144		132
Net income attributable to Colgate-Palmolive Company	\$	618	\$	634	\$	1,780	\$	2,018
Earnings per common share, basic	\$	0.74	\$	0.75	\$	2.12	\$	2.39
Formings non-common shore, diluted	S	0.74	\$	0.75	Q	2.12	\$	2.38
Earnings per common share, diluted	Φ	U. /4	Ф	0.73	Ф	2,12	Ф	2.38

Condensed Consolidated Statements of Comprehensive Income

(Dollars in Millions) (Unaudited)

Three Months Ended Nine Months Ended September 30, September 30, 2022 2022 2021 2021 Net income including noncontrolling interests 682 \$ 681 \$ 1,924 \$ 2,150 Other comprehensive income (loss), net of tax: (116)(168)Cumulative translation adjustments (161)(227)Retirement plans and other retiree benefit adjustments 298 31 327 49 17 25 Gains (losses) on cash flow hedges (26)75 Total Other comprehensive income (loss), net of tax 111 (68)175 (94)Total Comprehensive income including noncontrolling 793 613 2,099 2,056 Less: Net income attributable to noncontrolling interests 64 47 144 132 Less: Cumulative translation adjustments attributable to noncontrolling interests (16)(2) (32)(5) Total Comprehensive income attributable to noncontrolling 45 127 interests 48 112 Total Comprehensive income attributable to Colgate-1,929 568 1,987 745 Palmolive Company

Condensed Consolidated Balance Sheets

(Dollars in Millions) (Unaudited)

	Sep	tember 30, 2022	De	ecember 31, 2021
Assets		_		
Current Assets				
Cash and cash equivalents	\$	938	\$	832
Receivables (net of allowances of \$67 and \$78, respectively)		1,425		1,297
Inventories		2,073		1,692
Other current assets		842		576
Total current assets		5,278		4,397
Property, plant and equipment:				
Cost		9,318		8,899
Less: Accumulated depreciation		(5,195)		(5,169)
		4,123		3,730
Goodwill		3,538		3,284
Other intangible assets, net		2,219		2,462
Deferred income taxes		182		193
Other assets		948		974
Total assets	\$	16,288	\$	15,040
Liabilities and Shareholders' Equity				
Current Liabilities				
Notes and loans payable	\$	16	\$	39
Current portion of long-term debt		13		12
Accounts payable		1,541		1,479
Accrued income taxes		433		436
Other accruals		2,489		2,085
Total current liabilities		4,492		4,051
Long-term debt		8,219		7,194
Deferred income taxes		551		395
Other liabilities		1,973		2,429
Total liabilities		15,235		14,069
Shareholders' Equity				
Common stock, \$1 par value (2,000,000,000 shares authorized, 1,465,706,360 shares issued)		1,466		1,466
Additional paid-in capital		3,518		3,269
Retained earnings		24,566		24,350
Accumulated other comprehensive income (loss)		(4,179)		(4,386)
Unearned compensation		_		(1)
Treasury stock, at cost		(24,749)		(24,089)
Total Colgate-Palmolive Company shareholders' equity		622		609
Noncontrolling interests		431		362
Total equity	-	1,053	-	971
Total liabilities and equity	\$	16,288	\$	15,040
		•		-

Condensed Consolidated Statements of Cash Flows

(Dollars in Millions) (Unaudited)

(Chaudicu)				
		Nine Mor		
		Septen 2022	iber 30	2021
Operating Activities	-			
Net income including noncontrolling interests	\$	1,924	\$	2,150
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operations:		,	•	,
Depreciation and amortization		410		414
Restructuring and termination benefits, net of cash		51		(19)
Stock-based compensation expense		105		107
Gain on the sale of land		(47)		_
Forward starting swap settlement		82		_
Loss on early extinguishment of debt		_		75
Deferred income taxes		(13)		(146)
Cash effects of changes in:				
Receivables		(171)		(198)
Inventories		(422)		(37)
Accounts payable and other accruals		9		(107)
Other non-current assets and liabilities		(45)		(20)
Net cash provided by (used in) operations		1,883		2,219
Investing Activities				
Capital expenditures		(475)		(374)
Purchases of marketable securities and investments		(239)		(118)
Proceeds from sale of marketable securities and investments		55		55
Payment for acquisitions, net of cash acquired		(817)		_
Proceeds from the sale of land		47		_
Other investing activities		1		(25)
Net cash provided by (used in) investing activities		(1,428)		(462)
Financing Activities				
Short-term borrowing (repayment) less than 90 days, net		(56)		205
Principal payments of debt		(2)		(118)
Proceeds from issuance of debt		1,513		119
Dividends paid		(1,206)		(1,183)
Purchases of treasury shares		(895)		(964)
Proceeds from exercise of stock options		398		282
Other financing activities		(38)		(9)
Net cash provided by (used in) financing activities		(286)		(1,668)
Effect of exchange rate changes on Cash and cash equivalents		(63)		(19)
Net increase (decrease) in Cash and cash equivalents		106		70
Cash and cash equivalents at beginning of the period		832		888
Cash and cash equivalents at end of the period	\$	938	\$	958
Supplemental Cash Flow Information				
Income toyog maid	•	600	¢.	7.40

See Notes to Condensed Consolidated Financial Statements.

\$

690 \$

742

Income taxes paid

Condensed Consolidated Statements of Changes in Shareholders' Equity

(Dollars in Millions) (Unaudited)

Three Months Ended September 30, 2022

Colgate-Palmolive Company Shareholders' Equity

	C	ommon Stock	A	Additional Paid-in Capital	(Unearned Compensation	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss) ⁽¹⁾	Noncontrolling Interests
Balance, June 30, 2022	\$	1,466	\$	3,402	\$		\$ (24,736)	\$ 24,342	\$ (4,306)	\$ 390
Net income		_		_		_	_	618	_	64
Other comprehensive income (loss), net of tax		_		_		_	_	_	127	(16)
Dividends (\$0.47 per share)		_		_		_	_	(394)	_	_
Stock-based compensation expense		_		60		_	_	_	_	_
Shares issued for stock options		_		73		_	73	_	_	_
Shares issued for restricted stock units		_		(16)		_	16	_	_	_
Treasury stock acquired		_		_		_	(104)	_	_	_
Other		_		(1)		_	2	_	_	(7)
Balance, September 30, 2022	\$	1,466	\$	3,518	\$		\$ (24,749)	\$ 24,566	\$ (4,179)	\$ 431

Three Months Ended September 30, 2021

Colgate-Palmolive Company Shareholders' Equity

				•••	r minon, c comp	 , ~	 		
	(Common Stock	Additional Paid-in Capital		Unearned Compensation	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss) ⁽¹⁾	 Noncontrolling Interests
Balance June 30, 2021	\$	1,466	\$ 3,085	\$		\$ (23,665)	\$ 23,946	\$ (4,368)	\$ 398
Net income		_	_		_	_	634	_	47
Other comprehensive income (loss), net of tax		_	_		_	_	_	(66)	(2)
Dividends (\$0.45 per share)		_	_		_	_	(379)	_	(7)
Stock-based compensation expense		_	49		_	_	_	_	_
Shares issued for stock options		_	53		_	87	_	_	_
Shares issued for restricted stock units		_	(14)		_	14	_	_	_
Treasury stock acquired		_	_		_	(251)	_	_	_
Other		_	1		_	(1)	_	_	_
Balance, September 30, 2021	\$	1,466	\$ 3,174	\$		\$ (23,816)	\$ 24,201	\$ (4,434)	\$ 436

⁽¹⁾ Accumulated other comprehensive income (loss) includes cumulative translation losses of \$3,545 at September 30, 2022 (\$3,321 at September 30, 2021) and \$3,398 at June 30, 2022 (\$3,207 at June 30, 2021), respectively, and unrecognized retirement plan and other retiree benefits costs of \$717 at September 30, 2022 (\$1,129 at September 30, 2021) and \$1,015 at June 30, 2022 (\$1,160 at June 30, 2021), respectively.

Condensed Consolidated Statements of Changes in Shareholders' Equity

(Dollars in Millions)

(Unaudited)

Nine Months Ended September 30, 2022

Colgate-Palmolive Company Shareholders' Equity

	(Common Stock	Additional Paid-in Capital	(Unearned Compensation	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss) ⁽¹⁾	Noncontrolling Interests
Balance, December 31, 2021	\$	1,466	\$ 3,269	\$	(1)	\$ (24,089)	\$ 24,350	\$ (4,386)	\$ 362
Net income		_	_		_	_	1,780	_	144
Other comprehensive income (loss), net of tax		_	_		_	_	_	207	(32)
Dividends (\$1.86 per share)*		_	_		_	_	(1,564)	_	(42)
Stock-based compensation expense		_	105		_	_	_	_	_
Shares issued for stock options		_	181		_	194	_	_	_
Shares issued for restricted stock units		_	(39)		_	39	_	_	_
Treasury stock acquired		_	_		_	(895)	_	_	_
Other		_	2		1	2	_	_	(1)
Balance, September 30, 2022	\$	1,466	\$ 3,518	\$	_	\$ (24,749)	\$ 24,566	\$ (4,179)	\$ 431

Nine Months Ended September 30, 2021

Colgate-Palmolive Company Shareholders' Equity

		Colgate-rannonve Company Shareholders Equity														
	(Common Stock		Additional Paid-in Capital		Unearned Compensation	,	Treasury Stock		Retained Earnings		Accumulated Other Comprehensive Income (Loss) ⁽¹⁾		Other Comprehensive		Noncontrolling Interests
Balance, December 31, 2020	\$	1,466	\$	2,969	\$	(1)	\$	(23,045)	\$	23,699	\$	(4,345)	\$	358		
Net income		_		_		_		_		2,018		_		132		
Other comprehensive income (loss), net of tax		_		_		_		_		_		(89)		(5)		
Dividends (\$1.79 per share)*		_		_		_		_		(1,516)		_		(49)		
Stock-based compensation expense		_		107		_		_		_		_		_		
Shares issued for stock options		_		120		_		167		_		_		_		
Shares issued for restricted stock units		_		(26)		_		26		_		_		_		
Treasury stock acquired		_		_		_		(964)		_		_		_		
Other		_		4		1		_		_		_		_		
Balance, September 30, 2021	\$	1,466	\$	3,174	\$		\$	(23,816)	\$	24,201	\$	(4,434)	\$	436		

⁽¹⁾ Accumulated other comprehensive income (loss) includes cumulative translation losses of \$3,545 at September 30, 2022 (\$3,321 at September 30, 2021) and \$3,349 at December 31, 2021 (\$3,158 at December 31, 2020), respectively, and unrecognized retirement plan and other retiree benefits costs of \$717 at September 30, 2022 (\$1,129 at September 30, 2021) and \$1,044 at December 31, 2021 (\$1,178 at December 31, 2020), respectively.

^{*} Two dividends were declared in each of the first quarters of th

Notes to Condensed Consolidated Financial Statements

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

1. Basis of Presentation

The Condensed Consolidated Financial Statements reflect all normal recurring adjustments which, in management's opinion, are necessary for a fair statement of the results for interim periods. Results of operations for interim periods may not be representative of results to be expected for a full year. Colgate-Palmolive Company (together with its subsidiaries, the "Company" or "Colgate") reclassifies certain prior year amounts, as applicable, to conform to the current year presentation.

For a complete set of financial statement notes, including the Company's significant accounting policies, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (the "SEC").

2. Use of Estimates

Provisions for certain expenses, including income taxes, advertising and consumer promotion, are based on full year assumptions and are included in the accompanying Condensed Consolidated Financial Statements in proportion with estimated annual tax rates, the passage of time or estimated annual sales, as applicable.

3. Recent Accounting Pronouncements

In September 2022, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2022-04, "Liabilities-Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations." This ASU requires a buyer that uses supplier finance programs to make annual disclosures about the programs' key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period and associated rollforward information. The guidance is effective for the Company beginning on January 1, 2023, except for the rollforward, which is effective beginning on January 1, 2024. The Company is currently evaluating the impact of the new guidance and does not expect it to have a material impact on the Company's Consolidated Financial Statements.

In March 2022, the FASB issued ASU No. 2022-02, "Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures." This ASU eliminates the accounting guidance for troubled debt restructurings by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. This guidance is effective for the Company beginning on January 1, 2023 and is not expected to have a material impact on the Company's Consolidated Financial Statements.

In March 2022, the FASB issued ASU No. 2022-01, "Derivatives and Hedging (Topic 815): Fair Value Hedging-Portfolio Layer Method." This ASU clarifies the accounting and promotes consistency in reporting for hedges where the portfolio layer method is applied. This guidance is effective for the Company beginning on January 1, 2023 and is not expected to have an impact on the Company's Consolidated Financial Statements.

In November 2021, the FASB issued ASU No. 2021-10, "Government Assistance (Topic 832)." This ASU requires increased disclosure on an annual basis about transactions with domestic, foreign, local, regional and national governments, including entities related to those governments and intergovernmental organizations, that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance. This guidance was effective for the Company beginning on January 1, 2022 and did not have a material impact on the Company's Consolidated Financial Statements.

In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers." This ASU requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606)." This guidance is effective for the Company beginning on January 1, 2023 and is not expected to have a material impact on the Company's Consolidated Financial Statements.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

In March 2020, the FASB issued ASU No. 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting," which provides optional expedients and exceptions for applying generally accepted accounting principles ("GAAP") to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. In January 2021, the FASB issued ASU No. 2021-01, "Reference Rate Reform (Topic 848): Scope," which clarified that certain optional expedients and exceptions in Topic 848 apply to derivatives that are affected by the discounting transition due to reference rate reform. These ASUs were effective upon issuance and can be applied prospectively for contract modifications and hedging relationships through December 31, 2022. The guidance has not had and is not expected to have a material impact on the Company's Consolidated Financial Statements.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

4. Acquisitions

Red Collar Pet Foods

On September 30, 2022, the Company acquired a business, which operates three dry pet food manufacturing plants in the United States, from Red Collar Pet Foods Holdings, Inc. and Red Collar Pet Foods Holdings, L.P. (collectively, "Red Collar Pet Foods") for cash consideration of \$727 in order to further support the global growth of its Hill's Pet Nutrition business. The acquisition was financed with a combination of debt and cash and accounted for as a business combination in accordance with ASC 805.

The total purchase price of \$727 has been allocated to the net assets acquired based on their respective estimated fair values as follows:

Inventories	\$ 29
Property, plant and equipment	372
Goodwill	407
Current liabilities	(3)
Intangible liability	(16)
Deferred income taxes	(62)
Fair value of net assets acquired	\$ 727

Goodwill of \$407 was allocated to the Pet Nutrition segment. Goodwill will not be deductible for tax purposes.

The preliminary estimates of the fair value of identifiable assets acquired and liabilities assumed are subject to revisions, which may result in adjustments to the preliminary values discussed above. The Company expects to finalize the purchase price allocation no later than third quarter of 2023.

Pro forma results of operations have not been presented as the impact on the Company's Condensed Consolidated Financial Statements is not material.

Nutriamo S.r.l.

On April 28, 2022, the Company acquired the manufacturing assets of Nutriamo S.r.l. ("Nutriamo"), a canned pet food manufacturer based in Italy, which gives the Company additional capacity for the Hill's wet pet nutrition diets, particularly in Europe. This acquisition was accounted for as a business combination in accordance with ASC 805. The impact of this acquisition on the Company's Consolidated Financial Statements was not material.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

5. Restructuring and Related Implementation Charges

On January 27, 2022, the Company's Board of Directors (the "Board") approved a targeted productivity program (the "2022 Global Productivity Initiative"). The program is intended to reallocate resources towards the Company's strategic priorities and faster growth businesses, drive efficiencies in the Company's operations and streamline the Company's supply chain to reduce structural costs.

Implementation of the 2022 Global Productivity Initiative, which is now expected to be substantially completed by mid-year 2024, is still estimated to result in cumulative pretax charges, once all phases are approved and implemented, in the range of \$200 to \$240 (\$170 to \$200 aftertax), which is currently estimated to be comprised of the following: employee-related costs, including severance, pension and other termination benefits (75%); asset-related costs, primarily accelerated depreciation and asset write-downs (15%); and other charges (10%), which include contract termination costs, consisting primarily of implementation-related charges resulting directly from exit activities and the implementation of new strategies. It is estimated that approximately 80% to 90% of the charges will result in cash expenditures.

It is expected that the cumulative pretax charges, once all projects are approved and implemented, will relate to initiatives undertaken in North America (5%), Latin America (10%), Europe (45%), Asia Pacific (5%), Africa/Eurasia (15%), Hill's Pet Nutrition (5%) and Corporate (15%).

For the three months ended September 30, 2022, charges resulting from the 2022 Global Productivity Initiative were \$2 pretax (\$2 aftertax).

For the nine months ended September 30, 2022, charges resulting from the 2022 Global Productivity Initiative are reflected in the income statement as follows:

	Nine Months Ended Septembe	r 30,
	2022	
Selling, general and administrative expenses		4
Other (income) expense, net		75
Non-service related postretirement costs		13
Total 2022 Global Productivity Initiative charges, pretax	\$	92
Total 2022 Global Productivity Initiative charges, aftertax	\$	72

Restructuring and related implementation charges in the preceding table are recorded in the Corporate segment as these initiatives are predominantly centrally directed and controlled and are not included in internal measures of segment operating performance. Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments:

	Nine Months Ended September 30, 2022
North America	11 %
Latin America	16 %
Europe	16 %
Asia Pacific	9 %
Africa/Eurasia	12 %
Hill's Pet Nutrition	10 %
Corporate	26 %
Total	100 %

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

The following table summarizes the activity for the restructuring and related implementation charges discussed above and the related accruals:

Nine Months Ended September 30, 2022 **Employee-Related** Incremental Asset Total Costs Depreciation **Impairments** Other Balance at December 31, 2021 89 3 92 Charges (38)Cash Payments (2) (36)Charges against assets (13)(13)Foreign exchange (2) (2) 38 Balance at September 30, 2022

Employee-Related Costs primarily include severance and other termination benefits and are calculated based on long-standing benefit practices, written severance policies, local statutory requirements and, in certain cases, voluntary termination arrangements. Employee-Related Costs also include pension enhancements of \$13 for the nine months ended September 30, 2022, which are reflected as Charges against assets within Employee-Related Costs in the preceding tables as the corresponding balance sheet amounts are reflected as a reduction of pension assets or an increase in pension liabilities.

6. Inventories

Inventories by major class were as follows:

	September 30, 2022	December 31, 2021
Raw materials and supplies	\$ 551	\$ 505
Work-in-process	51	39
Finished goods	 1,572	1,248
Total Inventories, net	\$ 2,174	\$ 1,792
Non-current inventory, net	\$ (101)	\$ (100)
Current Inventories, net	\$ 2,073	\$ 1,692

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

7. Earnings Per Share

For the three months ended September 30, 2022 and 2021, earnings per share were as follows:

Three Months Ended September 30, 2022 September 30, 2021 Net income Net income attributable attributable to Colgate-Per to Colgate-Palmolive Shares Per **Shares** Palmolive Company (millions) Share Company (millions) Share 0.75 0.74 **Basic EPS** \$ 835.7 634 843.6 Stock options and restricted stock units 2.8 2.8 \$ 618 838.5 634 846.4 0.75 0.74 Diluted EPS

For the three months ended September 30, 2022 and 2021, the average number of stock options and restricted stock units that were anti-dilutive and not included in diluted earnings per share calculations were 2,891,324 and 2,318,391, respectively.

For the nine months ended September 30, 2022 and 2021, earnings per share were as follows:

		Nine Months Ended												
		Septeml	ber 30, 2022			September 30, 2021								
	Net income attributable to Colgate- Palmolive Company		Shares (millions)		Per Share	Net income attributable to Colgate-Palmolive Company		Shares (millions)		Per Share				
Basic EPS	\$	1,780	837.7	\$	2.12	\$	2,018	845.9	\$	2.39				
Stock options and restricted stock units			2.7					3.1						
Diluted EPS	\$	1,780	840.4	\$	2.12	\$	2,018	849.0	\$	2.38				

For the nine months ended September 30, 2022 and 2021, the average number of stock options and restricted stock units that were anti-dilutive and not included in diluted earnings per share calculations were 3,709,818 and 2,763,779, respectively.

Basic and diluted earnings per share are computed independently for each quarter and any year-to-date period presented. As a result of changes in the number of shares outstanding during the year and rounding, the sum of the quarters' earnings per share may not necessarily equal the earnings per share for any year-to-date period.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

8. Other Comprehensive Income (Loss)

Additions to and reclassifications out of Accumulated other comprehensive income (loss) attributable to the Company for the three months ended September 30, 2022 and 2021 were as follows:

		20		2021				
	Pre	tax	I	Net of Tax	Pr	etax		Net of Tax
Cumulative translation adjustments	\$	(93)	\$	(145)	\$	(83)	\$	(114)
Retirement plans and other retiree benefits:								
Net actuarial gain (loss) and prior service costs arising during the period		379		291		23		17
Amortization of net actuarial loss, transition and prior service costs (1)		9		7		18		14
Retirement plans and other retiree benefit adjustments	'	388		298		41		31
Cash flow hedges:								
Unrealized gains (losses) on cash flow hedges		(28)		(23)		18		15
Reclassification of (gains) losses into net earnings on cash flow hedges (2)		(4)		(3)		2		2
Gains (losses) on cash flow hedges	'	(32)		(26)		20		17
Total Other comprehensive income (loss)	\$	263	\$	127	\$	(22)	\$	(66)

⁽¹⁾ These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details.

There were no tax impacts on Other comprehensive income (loss) ("OCI") attributable to Noncontrolling interests.

Additions to and reclassifications out of Accumulated other comprehensive income (loss) attributable to the Company for the nine months ended September 30, 2022 and 2021 were as follows:

		202	2	2021					
	Pretax		Net of Tax	Pretax		Net of Tax			
Cumulative translation adjustments	\$ (57) 5	\$ (195)	\$ (111)	\$	(163)			
Retirement plans and other retiree benefits:									
Net actuarial gain (loss) and prior service costs arising during the period	3	79	291	_		2			
Amortization of net actuarial loss, transition and prior service costs (1)		16	36	61		47			
Retirement plans and other retiree benefit adjustments	4	25	327	61		49			
Cash flow hedges:									
Unrealized gains (losses) on cash flow hedges	1	13	88	22		17			
Reclassification of (gains) losses into net earnings on cash flow hedges (2)	((5)	(13)	9		8			
Gains (losses) on cash flow hedges		98	75	31		25			
Total Other comprehensive income (loss)	\$ 4	56 5	\$ 207	\$ (19)	\$	(89)			

⁽¹⁾ These components of Other comprehensive income (loss) are included in the computation of total pension cost. See Note 9, Retirement Plans and Other Retiree Benefits for additional details.

There were no tax impacts on OCI attributable to Noncontrolling interests.

⁽²⁾ These (gains) losses are reclassified into Cost of sales. See Note 12, Fair Value Measurements and Financial Instruments for additional details.

⁽²⁾ These (gains) losses are reclassified into Cost of sales. See Note 12, Fair Value Measurements and Financial Instruments for additional details.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

9. Retirement Plans and Other Retiree Benefits

Components of Net periodic benefit cost for the three and nine months ended September 30, 2022 and 2021 were as follows:

Three Months Ended September 30,

		Pension Benefits									Other Retiree Benefits			
		United States			International									
		2022		2021		2022		2021		2022		2021		
Service cost	\$		\$		\$	2	\$	3	\$	5	\$	7		
Interest cost		16		16		8		5		11		8		
Expected return on plan assets		(23)		(27)		(5)		(4)		_		_		
Amortization of actuarial loss (gain)		10		11		2		2		(3)		5		
Net periodic benefit cost	\$	3	\$		\$	7	\$	6	\$	13	\$	20		
Other postretirement charges		(1)		_		_		_		_		_		
Total pension cost	\$	2	\$	_	\$	7	\$	6	\$	13	\$	20		

Nine Months Ended September 30,

	1													
		Pension Benefits									Other Retiree Bene			
		United States			International									
		2022		2021		2022		2021		2022		2021		
Service cost	\$	1	\$	1	\$	10	\$	11	\$	16	\$	20		
Interest cost		48		46		14		14		30		26		
Expected return on plan assets		(75)		(81)		(10)		(14)		(1)				
Amortization of actuarial loss (gain)		33		35		5		8		8		18		
Net periodic benefit cost	\$	7	\$	1	\$	19	\$	19	\$	53	\$	64		
Other postretirement charges		12		_		_		_		1				
Total pension cost	\$	19	\$	1	\$	19	\$	19	\$	54	\$	64		
			_	-	_						_			

Other postretirement charges for the three months ended September 30, 2022 included an adjustment of \$1 related to the 2022 Global Productivity Initiative. Other postretirement charges for the nine months ended September 30, 2022 included pension and other charges of \$13 incurred pursuant to the 2022 Global Productivity Initiative.

For the three and nine months ended September 30, 2022 and 2021, the Company made no voluntary contributions to its U.S. postretirement plans.

During the third quarter of 2022, the Company amended its domestic postretirement plan to limit eligibility for certain existing employees and change the way coverage and subsidies are delivered for certain current and future retirees. As required, the Company remeasured the obligation for the domestic postretirement plan, which resulted in the reduction of the projected benefit obligation and a corresponding actuarial gain of \$398. The reduction of the projected benefit obligation and actuarial gain were primarily due to an increase in the discount rate since December 31, 2021 and the impact of the plan amendment. The actuarial gain was recorded in Accumulated other comprehensive income and will be amortized over future periods.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

10. Contingencies

As a global company serving consumers in more than 200 countries and territories, the Company is routinely subject to a wide variety of legal proceedings. These include disputes relating to intellectual property, contracts, product liability, marketing, advertising, foreign exchange controls, antitrust and trade regulation, as well as labor and employment, pension, data privacy and security, environmental and tax matters and consumer class actions. Management proactively reviews and monitors the Company's exposure to, and the impact of, environmental matters. The Company is party to various environmental matters and, as such, may be responsible for all or a portion of the cleanup, restoration and post-closure monitoring of several sites.

The Company establishes accruals for loss contingencies when it has determined that a loss is probable and that the amount of loss, or range of loss, can be reasonably estimated. Any such accruals are adjusted thereafter as appropriate to reflect changes in circumstances.

The Company also determines estimates of reasonably possible losses or ranges of reasonably possible losses in excess of related accrued liabilities, if any, when it has determined that a loss is reasonably possible and it is able to determine such estimates. For those matters disclosed below for which the amount of any potential losses can be reasonably estimated, the Company currently estimates that the aggregate range of reasonably possible losses in excess of any accrued liabilities is \$0 to approximately \$450 (based on current exchange rates). The estimates included in this amount are based on the Company's analysis of currently available information and, as new information is obtained, these estimates may change. Due to the inherent subjectivity of the assessments and the unpredictability of outcomes of legal proceedings, any amounts accrued or included in this aggregate range may not represent the ultimate loss to the Company. Thus, the Company's exposure and ultimate losses may be higher or lower, and possibly significantly so, than the amounts accrued or the range disclosed above.

Based on current knowledge, management does not believe that the ultimate resolution of loss contingencies arising from the matters discussed herein will have a material effect on the Company's consolidated financial position or its ongoing results of operations or cash flows. However, in light of the inherent uncertainties noted above, an adverse outcome in one or more matters could be material to the Company's results of operations or cash flows for any particular quarter or year.

Brazilian Matters

There are certain tax and civil proceedings outstanding, as described below, related to the Company's 1995 acquisition of the Kolynos oral care business from Wyeth (the "Seller").

The Brazilian internal revenue authority has disallowed interest deductions and foreign exchange losses taken by the Company's Brazilian subsidiary for certain years in connection with the financing of the Kolynos acquisition. The tax assessments with interest, penalties and any court-mandated fees, at the current exchange rate, are approximately \$113. This amount includes additional assessments received from the Brazilian internal revenue authority in April 2016 relating to net operating loss carryforwards used by the Company's Brazilian subsidiary to offset taxable income that had also been deducted from the authority's original assessments. The Company has been disputing the disallowances by appealing the assessments since October 2001.

In each of September 2015, February 2017, June 2018, April 2019 and September 2020, the Company lost an administrative appeal and subsequently challenged these assessments in the Brazilian federal courts. Currently, there are four appeals pending in the Lower Federal Court, and one case has progressed to the Federal Court of Appeals. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the disallowances are without merit and that the Company should ultimately prevail. The Company is challenging these disallowances vigorously.

In July 2002, the Brazilian Federal Public Attorney filed a civil action against the federal government of Brazil, Laboratorios Wyeth-Whitehall Ltda. (the Brazilian subsidiary of the Seller) and the Company, as represented by its Brazilian subsidiary, in the 6th. Lower Federal Court in the City of São Paulo, seeking to annul an April 2000 decision by the Brazilian Board of Tax Appeals that found in favor of the Seller's Brazilian subsidiary on the issue of whether it had incurred taxable capital gains as a result of the divestiture of Kolynos. The action seeks to make the Company's Brazilian

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

subsidiary jointly and severally liable for any tax due from the Seller's Brazilian subsidiary. The case has been pending since 2002, and the Lower Federal Court has not issued a decision. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the Company should ultimately prevail in this action. The Company is challenging this action vigorously.

In December 2005, the Brazilian internal revenue authority issued to the Company's Brazilian subsidiary a tax assessment with interest, penalties and any court-mandated fees of approximately \$50, at the current exchange rate, based on a claim that certain purchases of U.S. Treasury bills by the subsidiary and their subsequent disposition during the period 2000 to 2001 were subject to a tax on foreign exchange transactions. The Company had been disputing the assessment within the internal revenue authority's administrative appeals process. However, in November 2015, the Superior Chamber of Administrative Tax Appeals denied the Company's final administrative appeal, and the Company has filed a lawsuit in the Brazilian federal court. In the event the Company is unsuccessful in this lawsuit, further appeals are available within the Brazilian federal courts. Although there can be no assurances, management believes, based on the opinion of its Brazilian legal counsel, that the tax assessment is without merit and that the Company should ultimately prevail. The Company is challenging this assessment vigorously.

Competition Matter

Certain of the Company's subsidiaries were historically subject to actions and, in some cases, fines, by governmental authorities in a number of countries related to alleged competition law violations. Substantially all of these matters also involved other consumer goods companies and/or retail customers. The Company's policy is to comply with antitrust and competition laws and, if a violation of any such laws is found, to take appropriate remedial action and to cooperate fully with any related governmental inquiry. The status as of September 30, 2022 of such competition law matters pending against the Company during the nine months ended September 30, 2022 is set forth below.

• In July 2014, the Greek competition law authority issued a statement of objections alleging a restriction of parallel imports into Greece. The Company responded to this statement of objections. In July 2017, the Company received the decision from the Greek competition law authority in which the Company was fined \$11. The Company appealed the decision to the Greek courts. In April 2019, the Greek courts affirmed the judgment against the Company's Greek subsidiary, but reduced the fine to \$10.5 and dismissed the case against Colgate-Palmolive Company. The Company's Greek subsidiary and the Greek competition authority have appealed the decision to the Greek Supreme Court.

Talcum Powder Matters

The Company has been named as a defendant in civil actions alleging that certain talcum powder products that were sold prior to 1996 were contaminated with asbestos and/or caused mesothelioma and other cancers. Many of these actions involve a number of co-defendants from a variety of different industries, including suppliers of asbestos and manufacturers of products that, unlike the Company's products, were designed to contain asbestos. As of September 30, 2022, there were 224 individual cases pending against the Company in state and federal courts throughout the United States, as compared to 203 cases as of June 30, 2022 and 171 cases as of December 31, 2021. During the three months ended September 30, 2022, 33 new cases were filed and 12 cases were resolved by voluntary dismissal or settlement. During the nine months ended September 30, 2022, 72 cases were filed and 19 cases were resolved by voluntary dismissal or settlement. The values of the settlements in the quarter and year-to-date period presented were not material, either individually or in the aggregate, to the Company's results of operations in either such period.

A significant portion of the Company's costs incurred in defending and resolving these claims has been, and the Company believes that a portion of such costs will continue to be, covered by insurance policies issued by several primary, excess and umbrella insurance carriers, subject to deductibles, exclusions, retentions, policy limits and insurance carrier insolvencies.

While the Company and its legal counsel believe that these cases are without merit and intend to challenge them vigorously, there can be no assurances regarding the ultimate resolution of these matters.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

ERISA Matter

In June 2016, a putative class action claiming that residual annuity payments made to certain participants in the Colgate-Palmolive Company Employees' Retirement Income Plan (the "Plan") did not comply with the Employee Retirement Income Security Act was filed against the Plan, the Company and certain individuals (the "Company Defendants") in the United States District Court for the Southern District of New York (the "Court"). The relief sought includes recalculation of benefits, pre- and post-judgment interest and attorneys' fees. This action was certified as a class action in July 2017. In July 2020, the Court granted in part and denied in part the Company Defendants' motion for summary judgment and dismissed certain claims on consent of the parties. In August 2020, the Court granted the plaintiffs' motion for summary judgment on the remaining claims. The Company and the Plan are contesting this action vigorously and, in September 2020, appealed to the United States Court of Appeals for the Second Circuit. The appeal is currently pending.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

11. Segment Information

The Company operates in two product segments: Oral, Personal and Home Care; and Pet Nutrition.

The operations of the Oral, Personal and Home Care product segment are managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

The Company evaluates segment performance based on several factors, including Operating profit. The Company uses Operating profit as a measure of operating segment performance because it excludes the impact of Corporate-driven decisions related to interest expense and income taxes.

The accounting policies of the operating segments are generally the same as those described in Note 2, Summary of Significant Accounting Policies to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021. Intercompany sales have been eliminated. Corporate operations include costs related to stock options and restricted stock units, research and development costs, Corporate overhead costs, restructuring and related implementation charges and gains and losses on sales of non-core product lines and assets. The Company reports these items within Corporate operations as they relate to Corporate-based responsibilities and decisions and are not included in the internal measures of segment operating performance used by the Company to measure the underlying performance of the operating segments.

Net sales by segment were as follows:

	Three Mor Septen	 	Nine Months Ended September 30,						
	 2022	2021	2022			2021			
Net sales									
Oral, Personal and Home Care									
North America	\$ 958	\$ 931	\$	2,850	\$	2,765			
Latin America	997	931		2,970		2,745			
Europe	632	718		1,925		2,144			
Asia Pacific	709	731		2,131		2,142			
Africa/Eurasia	287	258		809		796			
Total Oral, Personal and Home Care	3,583	 3,569		10,685		10,592			
Pet Nutrition	872	845		2,653		2,426			
Total Net sales	\$ 4,455	\$ 4,414	\$	13,338	\$	13,018			

Approximately 70% of the Company's Net sales are generated from markets outside the U.S., with approximately 45% of the Company's Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe).

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts) (Unaudited)

The Company's Net sales of Oral, Personal and Home Care and Pet Nutrition products accounted for the following percentages of the Company's Net sales:

	Three Month Septembe		Nine Months September	
	2022	2021	2022	2021
Net sales				
Oral Care	44 %	44 %	44 %	44 %
Personal Care	19 %	20 %	19 %	20 %
Home Care	17 %	18 %	17 %	17 %
Pet Nutrition	20 %	18 %	20 %	19 %
Total Net sales	100 %	100 %	100 %	100 %

Operating profit by segment was as follows:

		Three Mon Septem			Nine Months Ended September 30,				
	2022 2021				2022		2021		
Operating profit									
Oral, Personal and Home Care									
North America	\$	198	\$	183	\$	557	\$	585	
Latin America		289		248		818		774	
Europe		127		178		410		524	
Asia Pacific		185		215		556		639	
Africa/Eurasia		66		44		160		153	
Total Oral, Personal and Home Care		865		868		2,501		2,675	
Pet Nutrition		201		233		617		661	
Corporate		(119)		(134)		(427)		(369)	
Total Operating profit	\$	947	\$	967	\$	2,691	\$	2,967	

Corporate Operating profit (loss) for the three and nine months ended September 30, 2022 included charges resulting from the 2022 Global Productivity Initiative of \$3 and \$79, respectively, a gain on the sale of land in Asia Pacific of \$47 in both periods and acquisition-related costs of \$17 in both periods. Corporate Operating profit (loss) for the nine months ended September 30, 2021 included a benefit related to a value-added tax matter in Brazil of \$26.

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

12. Fair Value Measurements and Financial Instruments

The Company uses available market information and other valuation methodologies in assessing the fair value of financial instruments. Judgment is required in interpreting market data to develop the estimates of fair value and, accordingly, changes in assumptions or the estimation methodologies may affect the fair value estimates. The Company is exposed to the risk of credit loss in the event of nonperformance by counterparties to financial instrument contracts; however, nonperformance is considered unlikely and any nonperformance is unlikely to be material, as it is the Company's policy to contract only with diverse, credit-worthy counterparties based upon both strong credit ratings and other credit considerations.

The Company is exposed to market risk from foreign currency exchange rates, interest rates and commodity price fluctuations. Volatility relating to these exposures is managed on a global basis by utilizing a number of techniques, including working capital management, sourcing strategies, selling price increases, selective borrowings in local currencies and entering into selective derivative instrument transactions, issued with standard features, in accordance with the Company's treasury and risk management policies, which prohibit the use of derivatives for speculative purposes and leveraged derivatives for any purpose. It is the Company's policy to enter into derivative instrument contracts with terms that match the underlying exposure being hedged.

The Company's derivative instruments include interest rate swap contracts, forward-starting interest rate swaps, foreign currency contracts and commodity contracts. The Company utilizes interest rate swap contracts to manage its targeted mix of fixed and floating rate debt, and these swaps are valued using observable benchmark rates (Level 2 valuation). The Company utilizes forward-starting interest rate swaps to mitigate the risk of variability in interest rate for future debt issuances and these swaps are valued using observable benchmark rates (Level 2 valuation). The Company utilizes foreign currency contracts, including forward and swap contracts, option contracts, local currency deposits and local currency borrowings to hedge portions of its foreign currency purchases, assets and liabilities arising in the normal course of business and the net investment in certain foreign subsidiaries. These contracts are valued using observable market rates (Level 2 valuation). Commodity futures contracts are utilized to hedge the purchases of raw materials used in production. These contracts are measured using quoted commodity exchange prices (Level 1 valuation). The duration of foreign currency and commodity contracts generally does not exceed 12 months.

The following table summarizes the fair value of the Company's derivative instruments and other financial instruments which are carried at fair value in the Company's Condensed Consolidated Balance Sheets at September 30, 2022 and December 31, 2021:

		Asset	s			Liabilities							
	Account	Fair Value				Account		Fair Value					
Designated derivative instruments			mber 30, 022	December 2021			September 30, 2022			nber 31, 021			
Interest rate swap contracts	Other current assets	\$	_	\$	5	Other accruals	\$	1	\$	_			
Forward-starting interest rate swaps	Other current assets		_		_	Other accruals		_		_			
Forward-starting interest rate swaps	Other assets		_		20	Other liabilities		_		21			
Foreign currency contracts	Other current assets		64		22	Other accruals		14		6			
Commodity contracts	Other current assets		_		2	Other accruals		_		_			
Total designated		\$	64	\$	49		\$	15	\$	27			
				-	_								
Other financial instruments													
Marketable securities	Other current assets	\$	208	\$	34								
Total other financial instrume	ents	\$	208	\$	34								

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts)
(Unaudited)

The carrying amount of cash, cash equivalents, marketable securities, accounts receivable and short-term debt approximated fair value as of September 30, 2022 and December 31, 2021. The estimated fair value of the Company's long-term debt, including the current portion, as of September 30, 2022 and December 31, 2021, was \$7,615 and \$7,651, respectively, and the related carrying value was \$8,232 and \$7,206, respectively. In August 2022, the Company issued \$500 of three-year Senior Notes at a fixed coupon rate of 3.100%, \$500 of five-year Senior Notes at a fixed coupon rate of 3.100% and \$500 of ten-year Senior Notes at a fixed coupon rate of 3.250%. The estimated fair value of long-term debt was derived principally from quoted prices on the Company's outstanding fixed-term notes (Level 2 valuation).

The following amounts were recorded on the Condensed Consolidated Balance Sheet related to the cumulative basis adjustment for fair value hedges as of:

	S	September 30, 2022	December 31, 2021
Long-term debt:			
Carrying amount of hedged item	\$	399	\$ 405
Cumulative hedging adjustment included in the carrying amount		_	5

The following tables present the notional values as of:

			Septem	iber 30, 2022		
	Foreign Currency Contracts	Foreign Currency Debt	Interest Rate Swaps	Forward- Starting Interest Rate Swaps	Commodity Contracts	Total
Fair Value Hedges	\$ 596	\$ —	\$ 400	\$	\$ —	\$ 996
Cash Flow Hedges	792	_	_	_	28	820
Net Investment Hedges	444	3,838	_	_	_	4,282

		December 31, 2021											
	C	Foreign urrency ontracts		Foreign Currency Debt		nterest te Swaps	I	Forward- Starting nterest Rate Swaps		Commodity Contracts		Total	
Fair Value Hedges	\$	566	\$	_	\$	400	\$	_	\$	_	\$	966	
Cash Flow Hedges		873		_		_		700		24		1,597	
Net Investment Hedges		173		4,600		_		_		_		4,773	

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts) (Unaudited)

The following tables present the location and amount of gains (losses) recognized on the Company's Condensed Consolidated Statements of Income:

	Three Months Ended September 30,												
				2022			2021						
		st of des		elling, general administrative expenses		Interest (income) (pense, net		Cost of sales		lling, general administrative expenses	(inc	erest come) ise, net	
Interest rate swaps designated as fair value hedges:													
Derivative instrument	\$	_	\$	_	\$	(12)	\$	_	\$	_	\$	2	
Hedged items		_		_		12		_		_		(2)	
Foreign currency contracts designated as fair value hedges:													
Derivative instrument		_		17		_		_		1		_	
Hedged items		_		(17)		_		_		(1)		_	
Foreign currency contracts designated as cash flow hedges:													
Amount reclassified from OCI		4		_		_		(2)		_		_	
Commodity contracts designated as cash flow hedges:													
Amount reclassified from OCI		_		_		_		_		_		_	
Total gain (loss) on hedges recognized in income	\$	4	\$	_	\$	_	\$	(2)	\$	_	\$	_	

	Nine Months Ended September 30,													
				2022			2021							
		Cost of sales		Selling, general d administrative expenses		Interest (income) xpense, net		Cost of sales		Selling, general d administrative expenses	Inte (inco expens	me)		
Interest rate swaps designated as fair value hedges:														
Derivative instrument	\$	_	\$	_	\$	(6)	\$	_	\$	_	\$	6		
Hedged items		_		_		6		_		_		(6)		
Foreign currency contracts designated as fair value hedges:														
Derivative instrument		_		31		_		_		(4)		_		
Hedged items		_		(31)		_		_		4		_		
Foreign currency contracts designated as cash flow hedges:														
Amount reclassified from OCI		9		_		_		(14)		_		_		
Commodity contracts designated as cash flow hedges:														
Amount reclassified from OCI		6		_		_		5		_		_		
Total gain (loss) on hedges recognized in ncome	\$	15	\$	_	\$	_	\$	(9)	\$	_	\$			

Notes to Condensed Consolidated Financial Statements (continued)

(Dollars in Millions Except Share and Per Share Amounts) (Unaudited)

The following table presents the location and amount of unrealized gains (losses) included in OCI:

Total unrealized gain (loss) on hedges recognized in OCI

	Three Months Ended					
		September 30,				
		2022	2021			
Foreign currency contracts designated as cash flow hedges:	·					
Gain (loss) recognized in OCI	\$	11 \$	8			
Forward-starting interest rate swaps designated as cash flow hedges:						
Gain (loss) recognized in OCI		(39)	12			
Commodity contracts designated as cash flow hedges:						
Gain (loss) recognized in OCI		_	(2)			
Foreign currency contracts designated as net investment hedges:						
Gain (loss) on instruments		12	19			
Gain (loss) on hedged items		(12)	(19)			
Foreign currency debt designated as net investment hedges:						
Gain (loss) on instruments		276	112			
Gain (loss) on hedged items		(276)	(112)			

(28)

18

	Nine Months Ended							
	September 30,							
	 2022	2021						
Foreign currency contracts designated as cash flow hedges:	 							
Gain (loss) recognized in OCI	\$ 24 \$	12						
Forward-starting interest rate swaps designated as cash flow hedges:								
Gain (loss) recognized in OCI	85	10						
Commodity contracts designated as cash flow hedges:								
Gain (loss) recognized in OCI	4	_						
Foreign currency contracts designated as net investment hedges:								
Gain (loss) on instruments	15	23						
Gain (loss) on hedged items	(15)	(23)						
Foreign currency debt designated as net investment hedges:								
Gain (loss) on instruments	636	261						
Gain (loss) on hedged items	(636)	(261)						
Total unrealized gain (loss) on hedges recognized in OCI	\$ 113 \$	22						

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Executive Overview

Business Organization

Colgate-Palmolive Company (together with its subsidiaries, "we," "us," "our," the "Company" or "Colgate") is a caring, innovative growth company reimagining a healthier future for all people, their pets and our planet. We seek to deliver sustainable, profitable growth and superior shareholder returns, as well as to provide Colgate people with an innovative and inclusive work environment. We do this by developing and selling products globally that make people's and their pets' lives healthier and more enjoyable and by embracing our sustainability and social impact and diversity, equity and inclusion ("DE&I") strategies across our organization.

We are tightly focused on two product segments: Oral, Personal and Home Care; and Pet Nutrition. Within these segments, we follow a closely defined business strategy to grow our key product categories and increase our overall market share. Within the categories in which we compete, we prioritize our efforts based on their capacity to maximize the use of the organization's core competencies and strong global equities and to deliver sustainable, profitable long-term growth.

Operationally, we are organized along geographic lines with management teams having responsibility for the business and financial results in each region. We compete in more than 200 countries and territories worldwide with established businesses in all regions contributing to our sales and profitability. Approximately 70% of our Net sales are generated from markets outside the U.S., with approximately 45% of our Net sales coming from emerging markets (which consist of Latin America, Asia (excluding Japan), Africa/Eurasia and Central Europe). This geographic diversity and balance help to reduce our exposure to business and other risks in any one country or part of the world.

The Oral, Personal and Home Care product segment is managed geographically in five reportable operating segments: North America, Latin America, Europe, Asia Pacific and Africa/Eurasia, all of which sell primarily to a variety of traditional and eCommerce retailers, wholesalers, distributors, dentists and skin health professionals. Through Hill's Pet Nutrition, we also compete on a worldwide basis in the pet nutrition market, selling products principally through authorized pet supply retailers, veterinarians and eCommerce retailers. We also sell certain of our products direct-to-consumer. We are engaged in manufacturing and sourcing of products and materials on a global scale and have major manufacturing facilities, warehousing facilities and distribution centers in every region around the world.

On an ongoing basis, management focuses on a variety of key indicators to monitor business health and performance. These indicators include net sales (including volume, pricing and foreign exchange components), organic sales growth (net sales growth excluding the impact of foreign exchange, acquisitions and divestments), a non-GAAP financial measure, and gross profit margin, operating profit, net income and earnings per share, in each case, on a GAAP and non-GAAP basis, as well as measures used to optimize the management of working capital, capital expenditures, cash flow and return on capital. In addition, we review market share and other data to assess how our brands are performing within their categories on a global and regional basis. The monitoring of these indicators and our Code of Conduct and corporate governance practices help to maintain business health and strong internal controls. For additional information regarding non-GAAP financial measures and the Company's use of market share data and the limitations of such data, see "Non-GAAP Financial Measures" and "Market Share Information" below.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

COVID-19

The COVID-19 pandemic and government steps to reduce the spread and address the impact of COVID-19 have had and continue to have an impact on the way people live, work, interact and shop.

During the COVID-19 pandemic, many of the communities in which we manufacture, market and sell our products experienced and certain geographies, notably China, continue to experience "stay at home" orders, travel or movement restrictions and other government actions to address the pandemic. While the impact of COVID-19 on our business has largely abated at this time, uncertainties continue, particularly in China where we have substantial manufacturing facilities and business, and in the travel retail channel where we have experienced and continue to experience disruptions. We have also experienced certain disruptions to our global supply chain due to COVID-19, which have impacted and may continue to impact sales of and consumer access to our products. We have also witnessed changes in the purchasing patterns of our customers, including the nature and/or frequency of visits by consumers to retailers and dental, veterinary and skin health professionals and a shift in many markets to purchasing our products online. COVID-19 may continue to impact consumers' behavior, shopping patterns and consumption preferences.

While we currently expect to be able to continue operating our business as described above, uncertainty resulting from COVID-19 could result in an unforeseen additional disruption to our business, including our global supply chain and retailer network, and/or require us to incur additional operational costs.

Due primarily to the impact of the COVID-19 pandemic on the Filorga skin health business, in the fourth quarter of 2021, the Company recorded an impairment charge to adjust the carrying values of the indefinite-lived trademark and goodwill of its Filorga reporting unit to their respective fair values. As of the date of the annual goodwill and indefinite-lived impairment test, the fair value of the Filorga indefinite-lived trademark continues to approximate its carrying value while the fair value of the Filorga reporting unit exceeds its carrying value by less than 20%.

We continue to believe in the strength of the Filorga brand and remain confident about its long-term growth opportunities. Given the inherent uncertainties of estimating the future impacts of the COVID-19 pandemic, interest rates and inflation on macroeconomic conditions in general, and on the Filorga business in particular, actual results may differ from management's current estimates which could potentially result in additional impairment charges in future periods.

For more information about the anticipated COVID-19 impact, see "Outlook" below.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

The War in Ukraine

The war in Ukraine, which began in February 2022, and the related geopolitical tensions, have had and continue to have a significant impact on our operations in Ukraine and Russia, though it has not been material to our Condensed Consolidated Financial Statements. The safety of our employees and partners in Ukraine has been and remains our first priority. While our ability to do business in Ukraine has been significantly impacted, we remain committed to rebuilding our business there and to providing access to essential products to people in the region. We have suspended the importation and sales of all products in Russia other than essential health and hygiene products for everyday use and ceased all capital investments and media activities in Russia. While these actions have impacted our Eurasia business, they have not had a material impact on our consolidated results of operations, cash flow or financial condition. During the year ended December 31, 2021 and the nine months ended September 30, 2022, our Eurasia business constituted approximately 2% of our consolidated business (the majority of which was Russia). We also continue to monitor the impact of sanctions and export controls imposed in response to the war in Ukraine. The situation is rapidly evolving and significant uncertainties remain regarding the full impact of the war and the related impact on the global economy and geopolitical relations generally, and on our business in particular. We have seen and expect to continue to see the war's impact on the global economy and our business including, among other things, the cost of raw and packaging materials and commodities (including the price of oil and natural gas), supply chain and logistics challenges and foreign currency volatility. For more information about factors that could impact our business, including due to the war in Ukraine, see "Risk Factors" in Part II, Item 1A of our Quarterly Report for the quarter ended March 31, 2022 and Part I, Item 1A of our Annual Report on Form 10-K for the year

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Business Strategy

To achieve our business and financial objectives, we are focused on driving organic sales growth and long-term profitable growth through science-led innovation on our core businesses; leveraging faster growth in adjacent categories; expanding in high-growth channels and markets and delivering margin expansion through operating leverage and efficiency. We are also seeking to maximize the impact of our environmental, social and governance programs and leading in the development of human capital, including our sustainability and social impact and DE&I strategies, which we are working to integrate across our organization. We are strengthening our capabilities in areas such as innovation, digital, eCommerce and data and analytics, enabling us to be more responsive in today's rapidly changing world. In particular, we believe our digital transformation is of paramount importance to our success going forward. We continue to invest behind our brands, including through advertising, and to develop initiatives to build strong relationships with consumers, dental, veterinary and skin health professionals and traditional and eCommerce retailers. We also continue to broaden our eCommerce offerings, including direct-to-consumer and subscription services. We continue to believe that growth opportunities are greater in those areas of the world in which economic development and rising consumer incomes expand the size and number of markets for our products.

We are also changing the way we work to drive growth and how we approach innovation with focus, empowerment, experimentation and digitization to respond to the dynamic retail landscape and the evolving preferences of our customers and consumers. The retail landscape, the ease of new entrants into the market in many of our categories and the evolving preferences of our customers and consumers demand that we work differently and faster in an agile, authentic and culturally relevant manner to drive innovation.

The investments needed to drive growth are supported through continuous, Company-wide initiatives to lower costs and increase effective asset utilization. Through these initiatives, which are referred to as our funding-the-growth initiatives, we seek to become even more effective and efficient throughout our businesses. These initiatives are designed to reduce costs associated with direct materials, indirect expenses, distribution and logistics and advertising and promotional materials, among other things, and encompass a wide range of projects, examples of which include raw material substitution, reduction of packaging materials, consolidating suppliers to leverage volumes and increasing manufacturing efficiency through SKU reductions and formulation simplification. We also continue to prioritize our investments in high growth segments within our Oral Care, Personal Care and Pet Nutrition businesses.

Significant Items Impacting Comparability

On September 30, 2022, the Company acquired a business, which operates three dry pet food manufacturing plants in the United States, from Red Collar Pet Foods Holdings, Inc. and Red Collar Pet Foods Holdings, L.P. (collectively, "Red Collar Pet Foods") for \$727 in order to further support the global growth of the Hill's Pet Nutrition business. See Note 4, Acquisitions to the Consolidated Financial Statements for additional information.

In July 2022, one of the Company's subsidiaries in Asia Pacific completed the sale of land and recognized a pretax gain of \$47 (\$15 aftertax attributable to the Company).

On January 27, 2022, the Company's Board of Directors (the "Board") approved a targeted productivity program (the "2022 Global Productivity Initiative"). The program is intended to reallocate resources towards the Company's strategic priorities and faster growth businesses, drive efficiencies in the Company's operations and streamline the Company's supply chain to reduce structural costs. Implementation of the 2022 Global Productivity Initiative, which is now expected to be substantially completed by mid-year 2024, is still estimated to result in cumulative pretax charges, once all phases are approved and implemented, in the range of \$200 to \$240 (\$170 to \$200 aftertax), which is currently estimated to be comprised of the following: employee-related costs, including severance, pension and other termination benefits (75%); asset-related costs, primarily accelerated depreciation and asset write-downs (15%); and other charges (10%), which include contract termination costs, consisting primarily of implementation-related charges resulting directly from exit activities and the implementation of new strategies. It is estimated that 80% to 90% of the charges will result in cash expenditures. Annualized pretax savings are projected to be in the range of \$90 to \$110 (\$70 to \$85 aftertax), once all projects are approved and implemented. For more information regarding the 2022 Global Productivity Initiative, see "Restructuring and Related Implementation Charges" below.

In the three and nine months ended September 30, 2022, the Company incurred pretax costs of \$2 (aftertax costs of \$2) and \$92 (aftertax costs of \$72), respectively, resulting from the 2022 Global Productivity Initiative.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

In 2019, the Company received a favorable judgment regarding certain value-added taxes previously paid in Brazil. As a result of this favorable judgment, during the fourth quarter of 2019, the Company filed an application with the Brazilian government to recover value-added tax previously paid and recorded a benefit. In May 2021, the Brazilian Supreme Court issued a clarifying ruling allowing a higher deduction of state value-added tax when determining the taxable base. In light of this ruling, the Company recorded an additional benefit of \$26 pretax (\$20 aftertax) in the nine months ended September 30, 2021.

In 1990, the Company's Canadian subsidiary ("CP Canada"), issued C\$145 of Canadian dollar-denominated unsecured unsubordinated 12.85% guaranteed notes due October 4, 2030 (the "Canada notes"). On August 26, 2021, CP Canada redeemed the Canada notes and recorded a loss on the early extinguishment of debt of \$75 pretax (\$55 aftertax), which is included in Interest (income) expense, net in the Consolidated Statements of Income, representing the difference between the redemption price and the carrying amount of the debt extinguished.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Outlook

Looking forward, we expect global macroeconomic, political and market conditions to remain challenging, including as a result of inflation and rising interest rates. During the nine months ended September 30, 2022, all of our divisions experienced significantly higher raw and packaging material costs. We also incurred increased logistics costs due to volume and capacity constraints in the shipping and logistics industry, higher eCommerce demand and the impact of COVID-19 and the war in Ukraine. We expect this difficult cost environment to continue throughout 2022. We are taking additional pricing to try to offset these increases in raw and packaging materials and logistics costs. This may, in turn, negatively impact consumer demand for our products. Additionally, inflation is impacting the broader economy with consumers around the world facing widespread rising prices as well as rising interest rates resulting from measures to address inflation. Such inflation and rising interest rates may negatively impact consumer consumption or discretionary spending and/or change their purchasing patterns by foregoing purchasing certain of our products or by switching to "private label" or lower-priced brands or to our lower-priced product offerings. Although we continue to devote significant resources to support our brands and market our products at multiple price points, these changes could reduce demand for and sales volumes of our products or result in a shift in our product mix from higher margin to lower margin product offerings. In light of this challenging environment, we expect increased volatility across all of our categories and it is therefore difficult to predict category growth rates in the near term.

Given that approximately 70% of our Net sales originate in markets outside the U.S., we have experienced and will likely continue to experience volatile foreign currency fluctuations. As discussed above, we have also experienced higher raw and packaging material and logistics costs. While we have taken, and will continue to take, measures to mitigate the effect of these conditions, such as the 2022 Global Productivity Initiative and our funding-the-growth and revenue growth management initiatives, including additional pricing, in the current environment, it may become increasingly difficult to implement certain of these mitigation strategies. Should these conditions persist, they could adversely affect our future results.

While the global marketplace in which we operate has always been highly competitive, we continue to experience heightened competitive activity in certain markets from strong local competitors, from other large multinational companies, some of which have greater resources than we do, and from new entrants into the market in many of our categories. Such activities have included more aggressive product claims and marketing challenges, as well as increased promotional spending and geographic expansion.

We have been negatively affected by changes in the policies and practices of our trade customers in key markets, such as inventory destocking, fulfillment requirements, limitations on access to shelf space, delisting of our products and certain environmental, sustainability, supply chain and packaging standards or initiatives. In addition, the retail landscape in many of our markets continues to evolve as a result of the rapid growth of eCommerce, changing consumer preferences (as consumers increasingly shop online and via mobile and social applications) and the increased presence of alternative retail channels, such as subscription services and direct-to-consumer businesses. These trends have been magnified due to COVID-19 in many of our geographies. We plan to continue to invest behind our digital and analytics capabilities and higher growth businesses. The rapid growth in eCommerce and the emergence of alternative retail channels have created and may continue to create pricing pressures and/or adversely affect our relationships with our key retailers.

We continue to closely monitor the impact of the war in Ukraine, COVID-19 and the challenging market conditions discussed above on our business and the related uncertainties and risks. While we have taken, and will continue to take, measures to mitigate the effects of these conditions, we cannot estimate with certainty the full extent of their impact on our business, results of operations, cash flows and/or financial condition. For more information about factors that could impact our business, including due to the war in Ukraine and COVID-19, see "Risk Factors" in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021.

We believe that we are well prepared to meet the challenges ahead due to our strong financial condition, broad-based experience operating in challenging environments, resilient global supply chain and focused business strategy. Our strategy is based on driving organic sales growth and long-term profitable growth through science-led innovation within our core businesses, leveraging faster growth in adjacent categories, expanding in high-growth channels and markets and delivering margin expansion through operating leverage and efficiency. We are also seeking to maximize the impact of our environmental, social and governance programs and leading in the development of human capital, including our sustainability and social impact and DE&I strategies. Our commitment to these priorities, the strength of our brands, the breadth of our global footprint and a commitment to driving efficiency in cash generation should position us well to manage through the challenges we face and increase shareholder value over time.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Results of Operations

Three Months

Worldwide Net sales were \$4,455 in the third quarter of 2022, up 1.0% from the third quarter of 2021, due to net selling price increases of 11.5%, partially offset by volume declines of 4.5% and negative foreign exchange of 6.0%. Organic sales (Net sales excluding the impact of foreign exchange, acquisitions and divestments), a non-GAAP financial measure, increased 7.0% in the third quarter of 2022. A reconciliation of net sales growth to organic sales growth is provided under "Non-GAAP Financial Measures" below.

Net sales in the Oral, Personal and Home Care product segment were \$3,583 in the third quarter of 2022, up 0.5% from the third quarter of 2021, due to net selling price increases of 12.0%, partially offset by volume declines of 5.0% and negative foreign exchange of 6.5%. Organic sales in the Oral, Personal and Home Care product segment increased 7.0% in the third quarter of 2022.

The Company's share of the global toothpaste market was 39.7% on a year-to-date basis, up 0.3 share points from the year ago period, and its share of the global manual toothbrush market was 31.6% on a year-to-date basis, up 0.6 share points from the year ago period. Year-to-date market shares in toothpaste were up in North America and Europe and down in Latin America, Asia Pacific and Africa/Eurasia versus the comparable 2021 period. In the manual toothbrush category, year-to-date market shares were up in North America, down in Latin America and Africa/Eurasia and flat in Europe and Asia Pacific versus the comparable 2021 period. For additional information regarding market shares, see "Market Share Information" below.

Net sales in the Hill's Pet Nutrition segment were \$872 in the third quarter of 2022, up 3.0% from the third quarter of 2021, due to net selling price increases of 11.0%, partially offset by volume declines of 3.5% and negative foreign exchange of 4.5%. Organic sales in the Hill's Pet Nutrition segment increased 7.5% in the third quarter of 2022.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Gross Profit/Margin

Worldwide Gross profit decreased to \$2,548 in the third quarter of 2022 from \$2,623 in the third quarter of 2021, reflecting a decrease of \$98 resulting from lower Gross profit margin and an increase of \$23 resulting from higher Net sales.

Worldwide Gross profit margin decreased to 57.2% in the third quarter of 2022 from 59.4% in the third quarter of 2021. This decrease in Gross profit margin was due to significantly higher raw and packaging material costs (920 bps), partially offset by higher pricing (440 bps) and cost savings from the Company's funding-the-growth initiatives (260 bps).

		Three Months Ended September 30,					
		2022		2021			
Gross profit		\$	2,548 \$	2,623			
		Three Mon	ths Ended Septemb	er 30,			
		2022	2021	Basis Point Change			
Gross profit margin		57.2 %	59.4 %	(220)			
	32						

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Selling, General and Administrative Expenses

Selling, general and administrative expenses were \$1,634 in the third quarter of 2022 compared to \$1,636 in the third quarter of 2021. Selling, general and administrative expenses in the third quarter of 2022 included charges resulting from the 2022 Global Productivity Initiative. Excluding charges resulting from the 2022 Global Productivity Initiative in the third quarter of 2022, Selling, general and administrative expenses were \$1,633 in the third quarter of 2022 compared to \$1,636 in the third quarter of 2021.

Selling, general and administrative expenses as a percentage of Net sales decreased to 36.7% in the third quarter of 2022 from 37.1% in the third quarter of 2021. This decrease was driven by decreased advertising investment (50 bps), partially offset by higher overhead expenses (10 bps). Higher overhead expenses were driven by higher logistics costs (30 bps), partially offset by overhead efficiencies (20 bps). In the third quarter of 2022, advertising investment decreased as a percentage of Net sales to 10.9% from 11.4% in the third quarter of 2021, or 3.3% in absolute terms to \$486 as compared with \$503 in the third quarter of 2021.

	 Three Months Ended September 30,				
	2022		2021		
Selling, general and administrative expenses, GAAP	\$ 1,634	\$	1,636		
2022 Global Productivity Initiative	(1)		_		
Selling, general and administrative expenses, non-GAAP	\$ 1,633	\$	1,636		

	Three Months Ended September 30,					
	2022	2021	Basis Point Change			
Selling, general and administrative expenses as a percentage of Net sales	36.7 %	37.1 %	(40)			

Other (Income) Expense, Net

Other (income) expense, net was \$(33) and \$20 in the third quarter of 2022 and 2021, respectively. Other (income) expense, net in the third quarter of 2022 included charges resulting from the 2022 Global Productivity Initiative, a gain on the sale of land in Asia Pacific and acquisition-related costs. Excluding these items, Other (income) expense, net was \$(5) and \$20 in the third quarter of 2022 and 2021, respectively.

	Th	Three Months Ended September 30,					
	20	022	2021				
Other (income) expense, net, GAAP	\$	(33) \$	20				
2022 Global Productivity Initiative		(2)	_				
Gain on the sale of land in Asia Pacific		47	_				
Acquisition-related costs		(17)	_				
Other (income) expense, net, non-GAAP	\$	(5) \$	20				

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Operating Profit

Operating profit decreased 2% to \$947 in the third quarter of 2022 from \$967 in the third quarter of 2021. Operating profit in the third quarter of 2022 included charges resulting from the 2022 Global Productivity Initiative, a gain on the sale of land in Asia Pacific and acquisition-related costs. Excluding these items, Operating profit decreased 5% to \$920 in the third quarter of 2022 from \$967 in the third quarter of 2021.

Operating profit margin was 21.3% in the third quarter of 2022, a decrease of 60 bps compared to 21.9% in the third quarter of 2021. Excluding the items described above, Operating profit margin was 20.7% in the third quarter of 2022, a decrease of 120 bps compared to 21.9% in the third quarter of 2021. This decrease in Operating profit margin was due to a decrease in Gross profit (220 bps), partially offset by a decrease in Selling, general and administrative expenses (40 bps) and a decrease in Other (income) expense, net (60 bps), all as a percentage of Net sales.

	Three Months Ended September 30,							
	2022		2021	% Change				
Operating profit, GAAP	\$ 947	\$	967	(2)%				
2022 Global Productivity Initiative	3		_					
Gain on the sale of land in Asia Pacific	(47)		_					
Acquisition-related costs	17		_					
Operating profit, non-GAAP	\$ 920	\$	967	(5)%				

	Three Months Ended September 30,						
	2022	2021	Basis Point Change				
Operating profit margin, GAAP	21.3 %	21.9 %	(60)				
2022 Global Productivity Initiative	0.1 %	— %					
Gain on the sale of land in Asia Pacific	(1.1)%	— %					
Acquisition-related costs	0.4 %	— %					
Operating profit margin, non-GAAP	20.7 %	21.9 %	(120)				

Non-Service Related Postretirement Costs

Non-service related postretirement costs were \$15 in the third quarter of 2022 as compared to \$16 in the third quarter of 2021. Non-service related postretirement costs in the third quarter of 2022 included an adjustment related to the 2022 Global Productivity Initiative. Excluding this adjustment, Non-service related postretirement costs were \$16 in the third quarter of 2022 and 2021.

	Th	Three Months Ended September 30,						
	2	022		2021				
Non-service related postretirement costs, GAAP	\$	15	\$	16				
2022 Global Productivity Initiative		1		_				
Non-service related postretirement costs, non-GAAP	\$	16	\$	16				

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Interest (Income) Expense, Net

Interest (income) expense, net was \$40 in the third quarter of 2022 as compared to \$98 in the third quarter of 2021. The decrease in Interest (income) expense, net in the third quarter of 2022 as compared to the third quarter of 2021 was primarily due to the loss on the early extinguishment of debt during the third quarter of 2021 of \$75. Excluding the loss on the early extinguishment of debt, Interest (income) expense, net was \$40 in the third quarter of 2022 as compared to \$23 in the third quarter of 2021, primarily due to higher interest rates.

	T	Three Months Ended September 30,						
		2022		2021				
Interest (income) expense, net, GAAP	\$	40	\$	98				
Loss on early extinguishment of debt		_		(75)				
Interest (income) expense, net, non-GAAP	\$	40	\$	23				

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Net Income Attributable to Colgate-Palmolive Company and Earnings Per Share

Net income attributable to Colgate-Palmolive Company in the third quarter of 2022 decreased to \$618 from \$634 in the third quarter of 2021, and Earnings per common share on a diluted basis decreased to \$0.74 per share in the third quarter of 2022 from \$0.75 in the third quarter of 2021. Net Income attributable to Colgate-Palmolive Company in the third quarter of 2022 included charges resulting from the 2022 Global Productivity Initiative, a gain on the sale of land in Asia Pacific and acquisition-related costs, and Net income attributable to Colgate-Palmolive Company in the third quarter of 2021 included a loss on the early extinguishment of debt.

Excluding the items described above in both periods as applicable, Net income attributable to Colgate-Palmolive Company in the third quarter of 2022 decreased 10% to \$620 from \$689 in the third quarter of 2021, and Earnings per common share on a diluted basis decreased 9% to \$0.74 in the third quarter of 2022 from \$0.81 in the third quarter of 2021.

Three Months Ended September 30, 2022 Net Income Including Income Provision Less: Income Attributable Net Income Attributable Diluted To Colgate-Palmolive Company Earnings Per Share⁽²⁾ Noncontrolling Before For Income to Noncontrolling Income Taxes Taxes⁽¹⁾ Interests Interests 892 \$ \$ As Reported GAAP \$ 210 682 \$ 64 618 0.74 2022 Global Productivity Initiative 2 2 2 Gain on the sale of land in Asia Pacific (47)(11)(36)(21)(15)(0.02)Acquisition-related costs 15 15 0.02 17 2 201 663 43 864 620 0.74 \$ Non-GAAP

Three Months Ended September 30, 2021

	Timee Woman's Ended September 30, 2021									
	Income Before Income Taxes		Provision For Income Taxes ⁽¹⁾		Net Income Including Noncontrolling Interests		Net Income Attributable To Colgate-Palmolive Company		Diluted Earnings Per Share ⁽²⁾	
As Reported GAAP	\$	853	\$	172	\$	681	\$	634	\$	0.75
Loss on early extinguishment of debt		75		20		55		55		0.06
Non-GAAP	\$	928	\$	192	\$	736	\$	689	\$	0.81

⁽¹⁾ The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Net Sales and Operating Profit by Segment

Oral, Personal and Home Care

North America

	 Three Months Ended September 30,					
	2022 2021		Change			
Net sales	\$ 958	\$	931	3.0 %		
Operating profit	\$ 198	\$	183	8 %		
% of Net sales	20.7 %)	19.7 %	100 bps		

Net sales in North America increased 3.0% in the third quarter of 2022 to \$958, driven by net selling price increases of 9.0%, partially offset by volume declines of 5.5% and negative foreign exchange of 0.5%. Organic sales in North America increased 3.5% in the third quarter of 2022. Organic sales growth was led by the United States.

The increase in organic sales in North America in the third quarter of 2022 versus the third quarter of 2021 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste category. The increase in Personal Care was primarily due to organic sales growth in the liquid hand soap and bar soap categories, partially offset by organic sales declines in the skin health category. The increase in Home Care was primarily due to organic sales growth in the hand dish category.

Operating profit in North America increased 8% in the third quarter of 2022 to \$198, or 100 bps to 20.7% as a percentage of Net sales. This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (10 bps) and a decrease in Selling, general and administrative expenses (130 bps), both as a percentage of Net sales. This increase in Gross profit was primarily due to higher pricing and cost savings from the Company's funding-the-growth initiatives (280 bps), partially offset by significantly higher raw and packaging material costs (680 bps). This decrease in Selling, general and administrative expenses was primarily due to lower overhead expenses (110 bps).

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Latin America

	Three Months Ended September 30,				
	2022 2021		Change		
Net sales	\$ 997	\$	931	7.0 %	
Operating profit	\$ 289	\$	248	17 %	
% of Net sales	29.0 %)	26.6 %	240 bps	

Net sales in Latin America increased 7.0% in the third quarter of 2022 to \$997, driven by net selling price increases of 20.0%, partially offset by volume declines of 8.5% and negative foreign exchange of 4.5%. Organic sales in Latin America increased 11.5% in the third quarter of 2022. Organic sales growth was led by Brazil, Mexico, Argentina and Colombia.

The increase in organic sales in Latin America in the third quarter of 2022 versus the third quarter of 2021 was primarily due to increase in Oral Care and Personal Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The increase in Personal Care was primarily due to organic sales growth in the bar soap, underarm protection and hair care categories.

Operating profit in Latin America increased 17% in the third quarter of 2022 to \$289, or 240 bps to 29.0% as a percentage of Net sales. This increase in Operating profit as a percentage of Net sales was due to a decrease in Selling, general and administrative expenses (70 bps) and a decrease in Other (income) expense, net (180 bps), partially offset by a decrease in Gross profit (10 bps), all as a percentage of Net sales. This decrease in Gross profit was primarily due to significantly higher raw and packaging material costs (1,110 bps), partially offset by higher pricing and cost savings from the Company's funding-the-growth initiatives (350 bps). This decrease in Selling, general and administrative expenses was due to lower overhead expenses (70 bps). This decrease in Other (income) expense, net was primarily due to a value added tax refund in the third quarter of 2022.

Europe

	Three Months Ended September 30,					
	2022		2021	Change		
Net sales	\$ 632	\$	718	(12.0) %		
Operating profit	\$ 127	\$	178	(29) %		
% of Net sales	20.1 %)	24.8 %	(470) bps		

Net sales in Europe decreased 12.0% in the third quarter of 2022 to \$632, driven by volume declines of 2.5% and negative foreign exchange of 14.5%, partially offset by net selling price increases of 5.0%. Organic sales in Europe increased 2.5% in the third quarter of 2022. Organic sales growth was led by the United Kingdom, Poland and France, partially offset by organic sales declines in the Filorga business.

The increase in organic sales in Europe in the third quarter of 2022 versus the third quarter of 2021 was primarily due to an increase in Oral Care organic sales, partially offset by a decrease in Personal Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The decrease in Personal Care was primarily due to organic sales declines in the skin health and liquid hand soap categories, partially offset by organic sales growth in the body wash category.

Operating profit in Europe decreased 29% in the third quarter of 2022 to \$127, or 470 bps to 20.1% as a percentage of Net sales. This decrease in Operating profit as a percentage of Net sales was primarily due to a decrease in Gross profit (530 bps), partially offset by a decrease in Selling, general and administrative expenses (90 bps), both as a percentage of Net sales. This decrease in Gross profit was primarily due to significantly higher raw and packaging material costs (980 bps), partially offset by cost savings from the Company's funding-the-growth initiatives (240 bps) and higher pricing. This decrease in Selling, general and administrative expenses was due to decreased advertising investment (60 bps) and lower overhead expenses (30 bps), as overhead efficiencies (150 bps) more than offset higher logistics costs (120 bps).

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Asia Pacific

	 Three Months Ended September 30,			
	2022		2021	Change
Net sales	\$ 709	\$	731	(3.0) %
Operating profit	\$ 185	\$	215	(14) %
% of Net sales	26.1 %		29.4 %	(330) bps

Net sales in Asia Pacific decreased 3.0% in the third quarter of 2022 to \$709, driven by volume declines of 1.0% and negative foreign exchange of 8.0%, partially offset by net selling price increases of 6.0%. Organic sales in Asia Pacific increased 5.0% in the third quarter of 2022. Organic sales growth was led by the Greater China region, Australia and the Philippines.

The increase in organic sales in Asia Pacific in the third quarter of 2022 versus the third quarter of 2021 was primarily due to an increase in Oral Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories.

Operating profit in Asia Pacific decreased 14% in the third quarter of 2022 to \$185, or 330 bps to 26.1% as a percentage of Net sales. This decrease in Operating profit as a percentage of Net sales was primarily due to a decrease in Gross profit (310 bps) and an increase in Selling, general and administrative expenses (50 bps), both as a percentage of Net sales. This decrease in Gross profit was primarily due to significantly higher raw and packaging material costs (950 bps), partially offset by cost savings from the Company's funding-the-growth initiatives (360 bps) and higher pricing. This increase in Selling, general and administrative expenses was due to increased advertising investment (50 bps).

Africa/Eurasia

	 Three Months Ended September 30,					
	2022 2021		Change			
Net sales	\$ 287	\$	258	11.0 %		
Operating profit	\$ 66	\$	44	50 %		
% of Net sales	23.0 %	ı	17.1 %	590 bps		

Net sales in Africa/Eurasia increased 11.0% in the third quarter of 2022 to \$287, driven by net selling price increases of 26.5%, partially offset by volume declines of 6.5% and negative foreign exchange of 9.0%. Organic sales in Africa/Eurasia increased 20.0% in the third quarter of 2022. Organic sales growth was led by Turkiye and South Africa.

The increase in organic sales in Africa/Eurasia in the third quarter of 2022 versus the third quarter of 2021 was primarily due to increase in Oral Care and Personal Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The increase in Personal Care was primarily due to organic sales growth in the bar soap category.

Operating profit in Africa/Eurasia increased 50% in the third quarter of 2022 to \$66, or 590 bps to 23.0% as a percentage of Net sales. This increase in Operating profit as a percentage of Net sales was primarily due to an increase in Gross profit (380 bps) and a decrease in Selling, general and administrative expenses (190 bps), both as a percentage of Net sales. This increase in Gross profit was due to higher pricing and cost savings from the Company's funding-the-growth initiatives (280 bps), partially offset by significantly higher raw and packaging material costs (920 bps). This decrease in Selling, general and administrative was due to lower overhead expenses (150 bps) and decreased advertising investment (40 bps).

Effective April 1, 2022, Turkiye was designated as a hyper-inflationary economy in accordance with Accounting Standard Codification ("ASC") Topic 830, "Foreign Currency Matters." Consequently, the functional currency for the Company's Turkish subsidiary is the U.S. dollar and the impact of Turkish currency fluctuations has been and will be recorded in income. This designation has not had and is not expected to have a material impact on the Company's Consolidated Financial Statements.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Hill's Pet Nutrition

	Three Months Ended September 30,				
	2022 2021		Change		
Net sales	\$ 872	\$	845	3.0 %	
Operating profit	\$ 201	\$	233	(14) %	
% of Net sales	23.1 %	,)	27.6 %	(450) bps	

Net sales for Hill's Pet Nutrition increased 3.0% in the third quarter of 2022 to \$872, driven by net selling price increases of 11.0%, partially offset by volume declines of 3.5% and negative foreign exchange of 4.5%. Organic sales in Hill's Pet Nutrition increased 7.5% in the third quarter of 2022. Organic sales growth was led by the United States and Europe.

The increase in organic sales in the third quarter of 2022 was primarily due to organic sales growth in the wellness and therapeutic categories.

Operating profit in Hill's Pet Nutrition decreased 14% in the third quarter of 2022 to \$201, or 450 bps to 23.1% as a percentage of Net sales. This decrease in Operating profit as a percentage of Net sales was primarily due to a decrease in Gross profit (540 bps), partially offset by a decrease in Selling, general and administrative expenses (100 bps), both as a percentage of Net sales. This decrease in Gross profit was primarily due to significantly higher raw and packaging material costs (890 bps), partially offset by higher pricing and cost savings from the Company's funding-the-growth initiatives (80 bps). This decrease in Selling, general and administrative expenses was due to decreased advertising investment (170 bps), partially offset by higher overhead expenses (70 bps), as higher logistics costs (110 bps) more than offset overhead efficiencies (40 bps).

Corporate

Operating profit (loss) related to Corporate was \$(119) in the third quarter of 2022 as compared to \$(134) in the third quarter of 2021. In the third quarter of 2022, Corporate Operating profit (loss) included charges of \$3 resulting from the 2022 Global Productivity Initiative, a gain on the sale of land in Asia Pacific of \$47 and acquisition-related costs of \$17.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Nine Months

Worldwide Net sales were \$13,338 in the first nine months of 2022, up 2.5% as compared to the first nine months of 2021 due to net selling price increases of 8.5%, partially offset by volume declines of 2.0% and negative foreign exchange of 4.0%. Organic sales increased 6.5% in the first nine months of 2022.

Net sales in the Oral, Personal and Home Care product segment were \$10,685 in the first nine months of 2022, an increase of 1.0% as compared to the first nine months of 2021 due to net selling price increases of 7.5%, partially offset by volume declines of 2.5% and negative foreign exchange of 4.0%. Organic sales in the Oral, Personal and Home Care product segment increased 5.0% in the first nine months of 2022.

The increase in organic sales in the first nine months of 2022 versus the first nine months of 2021 was due to increases in Oral Care, Personal Care and Home Care organic sales. The increase in Oral Care was primarily due to organic sales growth in the toothpaste and manual toothbrush categories. The increase in Personal Care was primarily due to organic sales growth in the bar soap and underarm protection categories, partially offset by organic sales declines in the skin health category. The increase in Home Care was primarily due to organic sales growth in the fabric softener and surface cleaners categories.

Net sales in the Hill's Pet Nutrition segment were \$2,653 in the first nine months of 2022, an increase of 9.5% from the first nine months of 2021 due to volume growth of 2.0% and net selling price increases of 11.0%, partially offset by negative foreign exchange of 3.5%. Organic sales in the Hill's Pet Nutrition segment increased 13.0% in the first nine months of 2022.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Net Sales and Operating Profit by Segment

Net sales and Operating profit by segment were as follows:

	Nine	Nine Months Ended September 30		
		2022		2021
Net sales				
Oral, Personal and Home Care				
North America	\$	2,850	\$	2,765
Latin America		2,970		2,745
Europe		1,925		2,144
Asia Pacific		2,131		2,142
Africa/Eurasia		809		796
Total Oral, Personal and Home Care		10,685		10,592
Pet Nutrition		2,653		2,426
Total Net sales	\$	13,338	\$	13,018
Operating profit				
Oral, Personal and Home Care				
North America	\$	557	\$	585
Latin America		818		774
Europe		410		524
Asia Pacific		556		639
Africa/Eurasia		160		153
Total Oral, Personal and Home Care		2,501		2,675
Pet Nutrition		617		661
Corporate		(427)		(369)
Total Operating profit	\$	2,691	\$	2,967

Within the Oral, Personal and Home Care product segment, North America Net sales increased 3.0% driven by net selling price increases of 4.0%, partially offset by volume declines of 0.5% and negative foreign exchange of 0.5%. Organic sales in North America increased 3.5%. Latin America Net sales increased 8.0% driven by net selling price increases of 14.0%, partially offset by volume declines of 4.0% and negative foreign exchange of 2.0%. Organic sales in Latin America increased 10.0%. Europe Net sales decreased 10.5% driven by volume declines of 3.5% and negative foreign exchange of 10.5%, partially offset by net selling price increases of 3.5%. Organic sales in Europe was flat. Asia Pacific Net sales decreased 0.5% driven by volume declines of 0.5% and negative foreign exchange of 5.5%, partially offset by net selling price increases of 5.5%. Organic sales in Asia Pacific increased 5.0%. Africa/Eurasia Net sales increased 1.5% driven by net selling price increases of 20.5%, partially offset by volume declines of 10.0% and negative foreign exchange of 9.0%. Organic sales in Africa/Eurasia increased 10.5%.

In the first nine months of 2022, Operating profit (loss) related to Corporate was \$(427) as compared to \$(369) in the first nine months of 2021. Corporate Operating profit (loss) for the nine months ended September 30, 2022 included charges resulting from the 2022 Global Productivity Initiative of \$79, a gain on the sale of land in Asia Pacific of \$47 and acquisition-related costs of \$17. Corporate Operating profit (loss) for the first nine months of 2021 included a benefit related to a value-added tax matter in Brazil of \$26.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Gross Profit/Margin

Worldwide Gross profit decreased to \$7,674 in the first nine months of 2022 from \$7,816 in the first nine months of 2021, reflecting a decrease of \$329 resulting from lower Gross profit margin and an increase of \$187 resulting from higher Net sales.

Worldwide Gross profit margin decreased to 57.5% in the first nine months of 2022 from 60.0% in the first nine months of 2021, primarily due to higher raw and packaging material costs (770 bps), partially offset by higher pricing (320 bps) and cost savings from the Company's funding-the-growth initiatives (210 bps).

	Nine M	Nine Months Ended September 30,			
	2022		2021		
Gross profit	\$	7,674 \$	7,816		
			_		
	Nine Mont	hs Ended Septemb	er 30,		
	2022	2021	Basis Point Change		
Gross profit margin	57.5 %	60.0 %	(250)		

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased 3% to \$4,932 in the first nine months of 2022 from \$4,809 in the first nine months of 2021. Selling, general and administrative expenses in the first nine months of 2022 included charges resulting from the 2022 Global Productivity Initiative. Excluding these charges, Selling, general and administrative expenses increased to \$4,928 in the first nine months of 2022 from \$4,809 in the first nine months of 2021, reflecting higher overhead expenses of \$158 and decreased advertising investment of \$39.

Selling, general and administrative expenses as a percentage of Net sales increased to 37.0% in the first nine months of 2022 from 36.9% in the first nine months of 2021. Excluding charges resulting from the 2022 Global Productivity Initiative in the first nine months of 2022, Selling, general and administrative expenses as a percentage of Net sales remained flat at 36.9% as higher logistics costs (110 bps) were offset by decreased advertising investment (60 bps) and overhead efficiencies (50 bps).

In the first nine months of 2022, advertising investment decreased 2.5% in absolute terms to \$1,493 as compared with \$1,532 in the first nine months of 2021, or as a percentage of Net sales to 11.2% from 11.8% in the first nine months of 2021.

	Nine Months Ended September 30,			
		2022		2021
Selling, general and administrative expenses, GAAP	\$	4,932	\$	4,809
2022 Global Productivity Initiative		(4)		_
Selling, general and administrative expenses, non-GAAP	\$	4,928	\$	4,809

	Nine Months Ended September 30,			
	2022	2021	Basis Point Change	
Selling, general and administrative expenses as a percentage of Net sales, GAAP	37.0 %	36.9 %	10	
2022 Global Productivity Initiative	(0.1)	_		
Selling, general and administrative expenses as a percentage of Net sales, non-GAAP	36.9 %	36.9 %	_	

Other (Income) Expense, Net

Other (income) expense, net was \$51 and \$40 in the first nine months of 2022 and 2021, respectively. Other (income) expense, net in the first nine months of 2022 included charges resulting from the 2022 Global Productivity Initiative, a gain on the sale of land in Asia Pacific and acquisition-related costs. Other (income) expense, net in the first nine months of 2021 included a benefit related to a value-added tax matter in Brazil. Excluding these items in both periods as applicable, Other (income) expense, net was \$6 and \$66 in the first nine months of 2022 and 2021, respectively.

	Nin	Nine Months Ended September 30,			
		2022	2021		
Other (income) expense, net, GAAP	\$	51	\$ 40		
2022 Global Productivity Initiative		(75)	_		
Gain on the sale of land in Asia Pacific		47	_		
Acquisition-related costs		(17)	_		
Value-added tax matter in Brazil		<u> </u>	26		
Other (income) expense, net, non-GAAP	\$	6	\$ 66		

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Operating Profit

Operating profit decreased 9% to \$2,691 in the first nine months of 2022 from \$2,967 in the first nine months of 2021. Operating profit in the first nine months of 2022 included charges resulting from the 2022 Global Productivity Initiative, a gain on the sale of land in Asia Pacific and acquisition-related costs. Operating profit in the first nine months of 2021 included a benefit related to a value-added tax matter in Brazil. Excluding these items in both periods as applicable, Operating profit decreased to \$2,740 in the first nine months of 2022 from \$2,941 in the first nine months of 2021, due to a decrease in Gross profit and an increase in Selling, general and administrative expenses, partially offset by a decrease in Other (income) expense, net.

Operating profit margin was 20.2% in the first nine months of 2022, a decrease of 260 bps compared to 22.8% in the first nine months of 2021. Excluding the items described above in both periods as applicable, Operating profit margin was 20.5% in the first nine months of 2022, a decrease of 210 bps compared to 22.6% in the first nine months of 2021, due to a decrease in Gross profit (250 bps), partially offset by a decrease in Other (income) expense, net (40 bps), both as a percentage of Net sales.

	Nine Months Ended September 30,						
		2022		2021	% Change		
Operating profit, GAAP	\$	2,691	\$	2,967	(9)%		
2022 Global Productivity Initiative		79		_			
Gain on the sale of land in Asia Pacific		(47)		_			
Acquisition-related costs		17					
Value-added tax matter in Brazil		_		(26)			
Operating profit, non-GAAP	\$	2,740	\$	2,941	(7)%		

	Nine Mon	Nine Months Ended September 30,			
	2022	2021	Basis Point Change		
Operating profit margin, GAAP	20.2 %	22.8 %	(260)		
2022 Global Productivity Initiative	0.6	_			
Gain on the sale of land in Asia Pacific	(0.4)	_			
Acquisition-related costs	0.1	_			
Value-added tax matter in Brazil	_	(0.2)			
Operating profit margin, non-GAAP	20.5 %	22.6 %	(210)		

Non-Service Related Postretirement Costs

Non-service related postretirement costs were \$65 in the first nine months of 2022 as compared to \$52 in the first nine months of 2021. Non-service related postretirement costs in the first nine months of 2022 included charges resulting from the 2022 Global Productivity Initiative. Excluding these charges, Non-service related postretirement costs were \$52 in the first nine months of 2022 and 2021.

	Nir	Nine Months Ended September 30,				
	20	22		2021		
Non-service related postretirement costs, GAAP	\$	65	\$	52		
2022 Global Productivity Initiative		(13)		_		
Non-service related postretirement costs, non-GAAP	\$	52	\$	52		

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Interest (Income) Expense, Net

Interest (income) expense, net was \$98 in the first nine months of 2022 as compared to \$152 in the first nine months of 2021. The decrease in Interest (income) expense, net in the third quarter of 2022 as compared to the third quarter of 2021 was primarily due to the loss on the early extinguishment of debt during the third quarter of 2021 of \$75. Excluding the loss on the early extinguishment of debt, Interest (income) expense, net was \$98 in the first nine months of 2022 as compared to \$77 in the first nine months of 2021, primarily due to higher interest rates.

	Nine Months Ended September 30,				
	 2022		2021		
Interest (income) expense, net, GAAP	\$ 98	\$	152		
Loss on early extinguishment of debt	_		(75)		
Interest (income) expense, net, non-GAAP	\$ 98	\$	77		

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Income Taxes

The effective income tax rate was 23.5% for the third quarter of 2022 as compared to 20.2% for the third quarter of 2021.

The effective income tax rate was 23.9% for the first nine months of 2022 as compared to 22.2% for the first nine months of 2021. As reflected in the table below, the non-GAAP effective income tax rate was 23.7% for the first nine months of 2022, as compared to 22.3% in the comparable period of 2021.

The quarterly provision for income taxes is determined based on the Company's estimated full year effective income tax rate adjusted by the amount of tax attributable to infrequent or unusual items that are separately recognized on a discrete basis in the income tax provision in the quarter in which they occur. The Company's current estimate of its full year effective income tax rate before discrete period items is 23.8%, compared to 22.6% in 2021. The increase in the Company's full year effective tax rate before discrete period items is primarily driven by the impact of recently finalized U.S. tax regulations, which place greater restrictions on foreign taxes that are creditable against U.S. taxes on foreign-sourced income.

Three Months Ended September 30, 2022 2021 Income Before Provision For Effective Income Income Before Provision For Effective Income Income Taxes(1) Income Taxes Tax Rate(2) Income Taxes Income Taxes(1) Tax Rate(2) As Reported GAAP 892 \$ 210 23.5 % \$ 853 \$ 172 20.2 % 2022 Global Productivity Initiative 2 (0.1)Gain on the sale of land in Asia Pacific (11)0.1 (47)Acquisition-related costs 17 2 (0.2)Loss on early extinguishment of debt 75 20 0.5 23.3 % 201 928 192 864 20.7 % Non-GAAP

	Nine Months Ended September 30,								
			2022			2021			
			Provision For Income Taxes ⁽¹⁾	Effective Income Tax Rate ⁽²⁾	Income Before Income Taxes	Provision For Income Taxes ⁽¹⁾	Effective Income Tax Rate ⁽²⁾		
As Reported GAAP	\$	2,528	\$ 604	23.9 %	\$ 2,763	\$ 613	22.2 %		
2022 Global Productivity Initiative		92	19	(0.1)	_	_	_		
Gain on the sale of land in Asia Pacific		(47)	(11)	_	_	_	_		
Acquisition-related costs		17	2	(0.1)	_	_	_		
Value-added tax matter in Brazil		_	_	_	(26)	(6)	_		
Loss on early extinguishment of debt		_	_	_	75	20	0.1		
Non-GAAP	\$	2,590	\$ 614	23.7 %	\$ 2,812	\$ 627	22.3 %		

⁽¹⁾ The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

⁽²⁾ The impact of non-GAAP items on the Company's effective tax rate represents the difference in the effective tax rate calculated with and without the non-GAAP adjustment on Income before income taxes and Provision for income taxes.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

On August 16, 2022, the Inflation Reduction Act of 2022 ("IRA") was enacted. The Company is currently evaluating the impact of the IRA's tax provisions on its Consolidated Financial Statements, the most significant of which is the corporate alternative minimum tax. These tax provisions are effective for tax years beginning after December 31, 2022.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Net Income Attributable to Colgate-Palmolive Company and Earnings Per Share

Net income attributable to Colgate-Palmolive Company in the first nine months of 2022 decreased to \$1,780 from \$2,018 in the comparable 2021 period. Earnings per common share on a diluted basis decreased to \$2.12 in the first nine months of 2022 from \$2.38 in the comparable 2021 period. Net income attributable to Colgate-Palmolive Company in the first nine months of 2022 included charges resulting from the 2022 Global Productivity Initiative, a gain on the sale of land in Asia Pacific and acquisition-related costs. Net income attributable to Colgate-Palmolive Company in the comparable 2021 period included a benefit related to a value-added tax matter in Brazil and a loss on the early extinguishment of debt.

Excluding the items described above in both periods as applicable, Net income attributable to Colgate-Palmolive Company in the first nine months of 2022 decreased 10% to \$1,852 from \$2,053 in the first nine months of 2021, and Earnings per common share on a diluted basis decreased 9% to \$2.20 in the first nine months of 2022 from \$2.42 in the first nine months of 2021.

Nine Months Ended September 30, 2022 Income Net Income Less: Income Net Income Diluted Provision For Before Including Attributable to Attributable To Earnings Per Income Income Noncontrolling Noncontrolling Colgate-Palmolive Taxes Taxes(1) Interests Interests Company Share⁽²⁾ As Reported GAAP 2,528 604 1,924 144 1,780 2.12 2022 Global Productivity Initiative 92 19 73 1 72 0.08 Gain on the sale of land in Asia Pacific (47)(11)(36)(21)(15)(0.02)Acquisition-related costs 0.0217 2 15 15 614 1,976 1,852 2.20 2,590 124 Non-GAAP

	Nine Months Ended September 30, 2021									
		ne Before Provision For Net Income Including Noncontrolling Interests		Net Income Attributable To Colgate-Palmolive Company		Diluted Earnings Per Share ⁽²⁾				
As Reported GAAP	\$	2,763	\$	613	\$	2,150	\$	2,018	\$	2.38
Value-added tax matter in Brazil		(26)		(6)		(20)		(20)		(0.02)
Loss on early extinguishment of debt		75		20		55		55		0.06
Non-GAAP	\$	2,812	\$	627	\$	2,185	\$	2,053	\$	2.42

⁽¹⁾ The income tax effect on non-GAAP items is calculated based upon the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
(2) The impact of non-GAAP adjustments on diluted earnings per share may not necessarily equal the difference between "GAAP" and "non-GAAP" as a result of rounding.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Restructuring and Related Implementation Charges

On January 27, 2022, the Board approved the 2022 Global Productivity Initiative. The program is intended to reallocate resources towards the Company's strategic priorities and faster growth businesses, drive efficiencies in the Company's operations and streamline the Company's supply chain to reduce structural costs.

Implementation of the 2022 Global Productivity Initiative, which is now expected to be substantially completed by mid-year 2024, is still estimated to result in cumulative pretax charges, once all phases are approved and implemented, in the range of \$200 to \$240 (\$170 to \$200 aftertax), which is currently estimated to be comprised of the following: employee-related costs, including severance, pension and other termination benefits (75%); asset-related costs, primarily accelerated depreciation and asset write-downs (15%); and other charges (10%), which include contract termination costs, consisting primarily of implementation-related charges resulting directly from exit activities and the implementation of new strategies. It is estimated that approximately 80% to 90% of the charges will result in cash expenditures. Annualized pretax savings are projected to be in the range of \$90 to \$110 (\$70 to \$85 aftertax), once all projects are approved and implemented.

It is expected that the cumulative pretax charges, once all projects are approved and implemented, will relate to initiatives undertaken in North America (5%), Latin America (10%), Europe (45%), Asia Pacific (5%), Africa/Eurasia (15%), Hill's Pet Nutrition (5%) and Corporate (15%).

For the three months ended September 30, 2022, charges resulting from the 2022 Global Productivity Initiative, were \$2 pretax (\$2 aftertax).

For the nine months ended September 30, 2022, charges resulting from the 2022 Global Productivity Initiative are reflected in the income statement as follows:

	Nine Months Ended September 30,					
	•	2022				
Selling, general and administrative expenses	·	4				
Other (income) expense, net		75				
Non-service related postretirement costs		13				
Total 2022 Global Productivity Initiative charges, pretax	\$	92				
Total 2022 Global Productivity Initiative charges, aftertax	\$	72				

Restructuring and related implementation charges in the preceding table are recorded in the Corporate segment as these initiatives are predominantly centrally directed and controlled and are not included in internal measures of segment operating performance. Total charges incurred for the 2022 Global Productivity Initiative relate to initiatives undertaken by the following reportable operating segments:

	Nine Months Ended September 30,
	2022
North America	11 %
Latin America	16 %
Europe	16 %
Asia Pacific	9 %
Africa/Eurasia	12 %
Hill's Pet Nutrition	10 %
Corporate	26 %
Total	100 %

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

The following table summarizes the activity for the restructuring and related implementation charges discussed above and the related accruals:

		Nine Months Ended September 30,									
	Employee- Cost		Incremental Depreciation	Asset Impairments	Other	Total					
Balance at December 31, 2021	\$	— \$	_	\$	\$ —	\$					
Charges		89	_	_	3	92					
Cash Payments		(36)	_	_	(2)	(38)					
Charges against assets		(13)	_	_	_	(13)					
Foreign exchange		(2)	_	_	_	(2)					
Balance at September 30, 2022	\$	38 \$		\$	\$ 1	\$ 39					

Employee-Related Costs primarily include severance and other termination benefits and are calculated based on long-standing benefit practices, written severance policies, local statutory requirements and, in certain cases, voluntary termination arrangements. Employee-Related Costs also include pension enhancements of \$13 for the nine months ended September 30, 2022, which are reflected as Charges against assets within Employee-Related Costs in the preceding tables as the corresponding balance sheet amounts are reflected as a reduction of pension assets or an increase in pension liabilities.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Non-GAAP Financial Measures

This Quarterly Report on Form 10-Q discusses certain financial measures on both a GAAP and a non-GAAP basis. The Company uses the non-GAAP financial measures described below internally in its budgeting process, to evaluate segment and overall operating performance and as a factor in determining compensation. The Company believes that these non-GAAP financial measures are useful in evaluating the Company's underlying business performance and trends; however, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similar measures presented by other companies.

Net sales growth (GAAP) and organic sales growth (Net sales growth excluding the impact of foreign exchange, acquisitions and divestments) (non-GAAP) are discussed in this Quarterly Report on Form 10-Q. Management believes the organic sales growth measure provides investors and analysts with useful supplemental information regarding the Company's underlying sales trends by presenting sales growth excluding the external factor of foreign exchange, as well as the impact of acquisitions and divestments, as applicable. A reconciliation of organic sales growth to Net sales growth for the three and nine months ended September 30, 2022 is provided below.

Selling, general and administrative expenses, Other (income) expense, net, Operating profit, Operating profit margin, Non-service related postretirement costs, effective income tax rate, Net income attributable to Colgate-Palmolive Company and Earnings per share on a diluted basis are discussed in this Quarterly Report on Form 10-Q both on a GAAP basis and excluding, as applicable, charges resulting from the 2022 Global Productivity Initiative, a gain on the sale of land in Asia Pacific, acquisition-related costs, a loss on the early extinguishment of debt and a benefit related to a value-added tax matter in Brazil. These non-GAAP financial measures exclude items that, either by their nature or amount, management would not expect to occur as part of the Company's normal business on a regular basis, such as restructuring charges, charges for certain litigation and tax matters, gains and losses from certain acquisitions, divestitures and certain other unusual, non-recurring items. Investors and analysts use these financial measures in assessing the Company's business performance, and management believes that presenting these financial measures on a non-GAAP basis provides them with useful supplemental information to enhance their understanding of the Company's underlying business performance and trends. These non-GAAP financial measures also enhance the ability to compare period-to-period financial results. A reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measures for the three and nine months ended September 30, 2022 and 2021 is presented within the applicable section of Results of Operations.

The following tables provide a quantitative reconciliation of Net sales growth to organic sales growth for the three and nine months ended September 30, 2022:

Three Months Ended September 30, 2022	Net Sales Growth (GAAP)	Foreign Exchange Impact	Acquisitions and Divestments Impact	Organic Sales Growth (Non-GAAP)
Oral, Personal and Home Care				
North America	3.0%	(0.5)%	<u> </u>	3.5%
Latin America	7.0%	(4.5)%	<u> </u>	11.5%
Europe	(12.0)%	(14.5)%	<u> </u>	2.5%
Asia Pacific	(3.0)%	(8.0)%	<u> </u>	5.0%
Africa/Eurasia	11.0%	(9.0)%	<u> </u>	20.0%
Total Oral, Personal and Home Care	0.5%	(6.5)%	<u>_%</u>	7.0%
Pet Nutrition	3.0%	(4.5)%	<u> </u>	7.5%
Total Company	1.0%	(6.0)%	<u> </u>	7.0%

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Nine Months Ended September 30, 2022	Net Sales Growth (GAAP)	Foreign Exchange Impact	Acquisitions and Divestments Impact	Organic Sales Growth (Non-GAAP)
Oral, Personal and Home Care				
North America	3.0%	(0.5)%	<u> </u>	3.5%
Latin America	8.0%	(2.0)%	<u> </u>	10.0%
Europe	(10.5)%	(10.5)%	<u> </u>	<u> % </u>
Asia Pacific	(0.5)%	(5.5)%	<u> </u>	5.0%
Africa/Eurasia	1.5%	(9.0)%	<u> </u> %	10.5%
Total Oral, Personal and Home Care	1.0%	(4.0)%	<u>%</u>	5.0%
Pet Nutrition	9.5%	(3.5)%	<u> </u> %	13.0%
Total Company	2.5%	(4.0)%	%	6.5%

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Liquidity and Capital Resources

The Company expects cash flow from operations and debt issuances will be sufficient to meet foreseeable business operating and recurring cash needs (including for debt service, dividends, capital expenditures, share repurchases and acquisitions). The Company believes its strong cash generation and financial position should continue to allow it broad access to global credit and capital markets.

Net cash provided by operations decreased 15% to \$1,883 in the first nine months of 2022, compared with \$2,219 in the comparable period of 2021, primarily due to higher levels of inventory (driven by higher raw and packaging material costs and increased levels to mitigate the risk of supply chain and logistics disruptions) and lower net income. The Company's working capital was (1.9%) as a percentage of Net sales as of September 30, 2022 as compared to (3.8%) as of September 30, 2021. The Company defines working capital as the difference between current assets (excluding Cash and cash equivalents and marketable securities, the latter of which is reported in Other current assets) and current liabilities (excluding short-term debt).

Investing activities used \$1,428 of cash in the first nine months of 2022, compared with \$462 in the comparable period of 2021. Investing activities in the first nine months of 2022 included the Company's acquisition of businesses from Red Collar Pet Foods and Nutriamo discussed in Note 4, Acquisitions to the Consolidated Financial Statements.

Capital spending was \$475 in the first nine months of 2022 compared to \$374 in the comparable period of 2021. Capital expenditures for 2022 are expected to be approximately 3.5% to 4.0% of Net sales. The Company continues to focus its capital spending on projects that are expected to yield high aftertax returns.

Financing activities used \$286 of cash during the first nine months of 2022, compared with \$1,668 used in the comparable period of 2021. This primarily reflects higher proceeds from the issuance of debt in the first nine months of 2022 compared with the comparable period of 2021.

Long-term debt, including the current portion, increased to \$8,232 as of September 30, 2022, as compared to \$7,206 as of December 31, 2021, and total debt was \$8,248 as of September 30, 2022, as compared to \$7,245 as of December 31, 2021. The Company's debt issuances support the Company's capital structure objectives of funding its business and growth initiatives while minimizing its risk-adjusted cost of capital.

In August 2022, the Company issued \$500 of three-year Senior Notes at a fixed coupon rate of 3.100%, \$500 of five-year Senior Notes at a fixed coupon rate of 3.100% and \$500 of ten-year Senior Notes at a fixed coupon rate of 3.250%.

In 1990, CP Canada, issued C\$145 of Canadian dollar-denominated unsecured unsubordinated 12.85% guaranteed notes due October 4, 2030. On August 26, 2021, CP Canada redeemed the Canada notes and recorded a loss on the early extinguishment of debt of \$75 pretax (\$55 aftertax), which is included in Interest (income) expense, net in the Consolidated Statements of Income, representing the difference between the redemption price and the carrying amount of the debt extinguished.

Domestic and foreign commercial paper outstanding was \$1,040 and \$1,633 as of September 30, 2022 and 2021, respectively. The average daily balances outstanding for commercial paper in the first nine months of 2022 and 2021 were \$1,823 and \$2,061, respectively. The Company classifies commercial paper and certain current maturities of notes payable as long-term debt when it has the intent and ability to refinance such obligations on a long-term basis, including, if necessary, by utilizing its unused lines of credit (including under the facilities discussed below) or by issuing long-term debt pursuant to an effective shelf registration statement. In August 2021, the Company entered into a new \$3,000 five-year revolving credit facility with a syndicate of banks for a five-year term expiring August 2026, which replaced, on substantially similar terms, the Company's \$2,650 revolving credit facility that was scheduled to expire in November 2024. Commitment fees related to the credit facility were not material.

Certain of the agreements with respect to the Company's bank borrowings contain financial and other covenants as well as cross-default provisions. Noncompliance with these requirements could ultimately result in the acceleration of amounts owed. The Company is in full compliance with all such requirements and believes the likelihood of noncompliance is remote. Refer to Note 6, Long Term Debt and Credit Facilities to the Consolidated Financial Statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 for further information about the Company's long-term debt and credit facilities.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

In the first quarter of 2022, the Company increased the quarterly common stock dividend to \$0.47 per share from \$0.45 per share previously, effective in the second quarter of 2022.

Cash and cash equivalents increased \$106 during the first nine months of 2022 to \$938 at September 30, 2022, compared to \$832 at December 31, 2021, the majority of which (\$909 and \$784 respectively) was held by the Company's foreign subsidiaries.

For additional information regarding liquidity and capital resources, please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2021.

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Market Share Information

Management uses market share information as a key indicator to monitor business health and performance. References to market share in this Quarterly Report on Form 10-Q are based on a combination of consumption and market share data provided by third-party vendors, primarily Nielsen, and internal estimates. All market share references represent the percentage of the dollar value of sales of our products, relative to all product sales in the category in the countries in which the Company competes and purchases data (excluding Venezuela from all periods).

Market share data is subject to limitations on the availability of up-to-date information. In particular, market share data is currently not generally available for certain retail channels, such as eCommerce or certain discounters. The Company measures year-to-date market shares from January 1 of the relevant year through the most recent period for which market share data is available, which typically reflects a lag time of one or two months. The Company believes that the third-party vendors we use to provide data are reliable, but we have not verified the accuracy or completeness of the data or any assumptions underlying the data. In addition, market share information calculated by the Company may be different from market share information calculated by other companies due to differences in category definitions, the use of data from different countries, internal estimates and other factors.

Cautionary Statement on Forward-Looking Statements

This Quarterly Report on Form 10-Q may contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 or by the SEC in its rules, regulations and releases that set forth anticipated results based on management's current plans and assumptions. Such statements may relate, for example, to sales or volume growth, net selling price increases, organic sales growth, profit or profit margin levels, earnings per share levels, financial goals, the impact of foreign exchange volatility, the impact of COVID-19, the impact of the war in Ukraine, cost-reduction plans, including the 2022 Global Productivity Initiative, tax rates, interest rates, new product introductions and digital capabilities, commercial investment levels, acquisitions, divestitures, share repurchases, or legal or tax proceedings, among other matters. These statements are made on the basis of the Company's views and assumptions as of this time and the Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. Moreover, the Company does not, nor does any other person, assume responsibility for the accuracy and completeness of those statements. The Company cautions investors that any such forward-looking statements are not guarantees of future performance and that actual events or results may differ materially from those statements. Actual events or results may differ materially because of factors that affect international businesses and global economic conditions, as well as matters specific to the Company and the markets it serves, including the uncertain macroeconomic and political environment in different countries, including as a result of inflation and rising interest rates, and its effect on consumer spending habits, foreign currency rate fluctuations, exchange controls, tariffs, price or profit controls, labor relations, changes in foreign or domestic laws, or regulations or their interpretation, political and fiscal developments, including changes in trade, tax and immigration policies, increased competition and evolving competitive practices (including from the growth of eCommerce and the entry of new competitors and business models), the ability to operate and respond effectively during a pandemic, epidemic or widespread public health concern, including COVID-19, ability to manage disruptions in our global supply chain and/or key office facilities, ability to manage the availability and cost of raw and packaging materials and logistics costs, the ability to maintain or increase selling prices as needed, changes in the policies of retail trade customers, the emergence of alternative retail channels, the growth of eCommerce and the rapidly changing retail landscape (as consumers increasingly shop online), the ability to develop innovative new products, the ability to continue lowering costs and operate in an agile manner, the ability to maintain the security of our information technology systems from a cyber-security incident or data breach, the ability to address the effects of climate change and achieve our sustainability and social impact goals, the ability to complete acquisitions and divestitures as planned, the ability to successfully integrate acquired businesses, the ability to attract and retain key employees and integrate DE&I initiatives across our organization, the uncertainty of the outcome of legal proceedings, whether or not the Company believes they have merit, and the ability to address uncertain or unfavorable global economic conditions, including inflation, disruptions in the credit markets and tax matters. For information about these and other factors that could impact the Company's business and cause actual results to differ materially from forward-looking statements, refer to the Company's filings with the SEC (including, but not limited to, the information set forth under the captions "Risk Factors" and "Cautionary Statement on Forward-Looking Statements" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and subsequent filings with the SEC).

Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in Millions Except Per Share Amounts)

Quantitative and Qualitative Disclosures about Market Risk

There is no material change in the information reported under Part II, Item 7, "Managing Foreign Currency, Interest Rate, Commodity Price and Credit Risk Exposure" contained in our Annual Report on Form 10-K for the year ended December 31, 2021.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company's management, under the supervision and with the participation of the Company's Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of September 30, 2022 (the "Evaluation"). Based upon the Evaluation, the Company's Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) are effective.

Changes in Internal Control Over Financial Reporting

The Company is in the process of upgrading its enterprise IT system to SAP S/4 HANA. This change has not had and is not expected to have a material impact on the Company's internal controls over financial reporting.

Except as noted above, there were no changes in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

For information regarding legal matters, please refer to Note 10, Contingencies to the Condensed Consolidated Financial Statements contained in Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in "Risk Factors" in Part 1, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2021 other than as set forth in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On March 10, 2022, the Board authorized the repurchase of shares of the Company's common stock having an aggregate purchase price of up to \$5 billion under a new share repurchase program (the "2022 Program"), which replaced a previously authorized share repurchase program. The Board also has authorized share repurchases on an ongoing basis to fulfill certain requirements of the Company's compensation and benefit programs. The shares are repurchased from time to time in open market or privately negotiated transactions at the Company's discretion, subject to market conditions, customary blackout periods and other factors.

The following table shows the stock repurchase activity for the three months in the quarter ended September 30, 2022:

Month	Total Number of Shares Purchased ⁽¹⁾	Ave	rage Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs ⁽²⁾	of S	proximate Dollar Value Shares That May Yet Be rchased Under the Plans or Programs ⁽³⁾ (in millions)
July 1 through 31, 2022	_	\$	_	_	\$	4,489
August 1 through 31, 2022	4,356	\$	82.17	_	\$	4,489
September 1 through 30, 2022	1,522,662	\$	74.45	1,460,400	\$	4,380
Total	1,527,018	\$	74.47	1,460,400		

⁽¹⁾ Includes share repurchases under the 2022 Program and those associated with certain employee elections under the Company's compensation and benefit programs.

(2) The difference between the total number of shares purchased and the total number of shares purchased as part of publicly announced plans or programs is

⁽²⁾ The difference between the total number of shares purchased and the total number of shares purchased as part of publicly announced plans or programs is 66,618 shares, which represents shares deemed surrendered to the Company to satisfy certain employee elections under the Company's compensation and benefit programs.

⁽³⁾ Includes approximate dollar value of shares that were available to be purchased under the publicly announced plans or programs that were in effect as of September 30, 2022.

Item 3.	<u>Defaults Upon Senior Securities</u>		
None.			
Item 4.	Mine Safety Disclosures		
Not Applicable.			
<u>Item 5.</u>	Other Information		
None.			
	61		

Item 6. Exhibits

Exhibit No.	Description	
31-A	Certificate of the Chairman of the Board, President and Chief Executive Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.*	
31-B	Certificate of the Chief Financial Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.*	
32	Certificate of the Chairman of the Board, President and Chief Executive Officer and the Chief Financial Officer of Colgate-Palmolive Company pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. § 1350.**	
101	The following materials from Colgate-Palmolive Company's Quarterly Report on Form 10-Q for the period ended September 30, 2022, formatted in Inline eXtensible Business Reporting Language (Inline XBRL): (i) the Condensed Consolidated Statements of Income; (ii) the Condensed Consolidated Statements of Comprehensive Income; (iii) the Condensed Consolidated Balance Sheets; (iv) the Condensed Consolidated Statements of Cash Flows; (v) Condensed Consolidated Statements of Changes in Shareholders' Equity; and (vi) Notes to Condensed Consolidated Financial Statements.	
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).	

^{*} Filed herewith.

^{**} Furnished herewith.

COLGATE-PALMOLIVE COMPANY SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	COLGATE-PALMOLIVE COMPANY
	(Registrant)
	Principal Executive Officer:
October 28, 2022	/s/ Noel R. Wallace
	Noel R. Wallace
	Chairman of the Board, President and Chief Executive Officer
	Principal Financial Officer:
October 28, 2022	/s/ Stanley J. Sutula III
	Stanley J. Sutula III
	Chief Financial Officer
	Principal Accounting Officer:
October 28, 2022	/s/ Gregory O. Malcolm
	Gregory O. Malcolm
	Vice President and Controller

I, Noel R. Wallace, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Colgate-Palmolive Company;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 28, 2022

/s/ Noel R. Wallace

Noel R. Wallace

Chairman of the Board, President and

Chief Executive Officer

I, Stanley J. Sutula III, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Colgate-Palmolive Company;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 28, 2022

/s/ Stanley J. Sutula III

Stanley J. Sutula III

Chief Financial Officer

The undersigned Chairman of the Board, President and Chief Executive Officer and Chief Financial Officer of Colgate-Palmolive Company each certify, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. § 1350, that:

- (1) the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (the "Report") which this statement accompanies fully complies with the requirements of Sections 13(a) and 15(d) of the Securities Exchange Act of 1934; and
- (2) information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Colgate-Palmolive Company.

Date: October 28, 2022

/s/ Noel R. Wallace

Noel R. Wallace
Chairman of the Board, President and
Chief Executive Officer

/s/ Stanley J. Sutula III
Stanley J. Sutula III
Chief Financial Officer